

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 66

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in *Cumulative List No. 13, 2009* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 66

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la *Liste récapitulative No. 13, 2009* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 66

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en *Cumulative List No. 13, 2009* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

abediterolum


abediterol

5-[(1*R*)-2-[[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1*H*)-one

abéditérol

5-[(1*R*)-2-[[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino]-1-hydroxyéthyl]-8-hydroxyquinoléin-2(1*H*)-one

abediterol

5-[(1*R*)-2-[[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietyl]-8-hidroxiquinolin-2(1*H*)-onaC₂₅H₃₀F₂N₂O₄**adomiparinum natricum**

adomiparin sodium

sodium salt of a low molecular mass heparin obtained by enzymatic depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 4-deoxy- α -L-*threo*-hex-4-enopyranuronic acid or its 4-hydroxy saturated derivative at the non-reducing end and a 2-amino-2-deoxy-D-glucopyranose derivative structure at the reducing end of their chain; the relative average molecular mass range is 5,500 to 9,000 daltons and a polydispersity of less than 1.5; the degree of sulfation is about 2.6 per disaccharidic unit

adomiparine sodique

sel sodique d'héparine de faible masse moléculaire obtenu par dépolymérisation enzymatique d'héparine de muqueuse intestinale de porc ; la majorité des composants possèdent une structure acide 4-déoxy- α -L-*thréo*-hex-4-énopyranuronique ou son dérivé saturé 4-hydroxylé à l'extrémité non réductrice de leur chaîne et une structure 2-amino-2-désoxy-D-glucopyranose à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative est en moyenne comprise entre 5500 et 9000 et son indice de polymolécularité est inférieure à 1,5 ; le degré de sulfatation est d'environ 2,6 par unité disaccharide.

adomiparina sódica

sal sódica de heparina de baja masa molecular obtenida por despolimerización enzimática de heparina de mucosa intestinal de cerdo; la mayoría de cuyos componentes tienen un ácido 4-desoxi- α -L-treo-hex-4-enopirranurónico o su derivado saturado 4-hidroxilado en el extremo no reductor de la cadena y una 2-amino-2-desoxi-D-glucopiranososa en el reductor; la masa molecular relativa media está comprendida entre 5500 y 9000 y su índice de polidispersión es inferior a 1,5; el grado de sulfatación es aproximadamente 2,6 por unidad de disacárido.

aganepagum

aganepag


5-{3-[(2S)-1-{4-[(1S)-1-hydroxyhexyl]phenyl}-5-oxopyrrolidin-2-yl]propyl}thiophene-2-carboxylic acid

aganépag

acide 5-{3-[(2S)-1-{4-[(1S)-1-hydroxyhexyl]phényl}-5-oxopyrrolidin-2-yl]propyl}thiophène-2-carboxylique

aganepag

ácido 5-{3-[(2S)-1-{4-[(1S)-1-hidroxihexil]fenil}-5-oxopirrolidin-2-il]propil}tiofeno-2-carboxílico

C₂₄H₃₁NO₄S**alisertibum**

alisertib


4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid

alisertib

acide 4-[[9-chloro-7-(2-fluoro-6-méthoxyphényl)-5H-pyrimido[5,4-d][2]benzazépin-2-yl]amino]-2-méthoxybenzoïque

alisertib

ácido 4-[[9-cloro-7-(2-fluoro-6-metoxifenil)-5H-pirimido[5,4-d][2]benzazepin-2-il]amino]-2-metoxibenzoico

C₂₇H₂₀ClFN₄O₄

alvelestatum

alvelestat


N-[5-(methanesulfonyl)pyridin-2-yl]methyl-6-methyl-5-(1-methyl-1*H*-pyrazol-5-yl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide

alvélestat

N-[5-(méthanesulfonyl)pyridin-2-yl]méthyl-6-méthyl-5-(1-méthyl-1*H*-pyrazol-5-yl)-2-oxo-1-[3-(trifluorométhyl)phényl]-1,2-dihydropyridine-3-carboxamide

alvelestat

N-[5-(metanosulfonyl)piridin-2-il]metil-6-metil-5-(1-metil-1*H*-pirazol-5-il)-2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridina-3-carboxamida

C₂₅H₂₂F₃N₅O₄S**amatuximabum #**

amatuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte-potentiating factor, MPF, CAK1)], chimeric monoclonal antibody; gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-37*01 - (IGHD)-IGHJ2*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-213')-disulfide with kappa light chain (1'-213') [*Mus musculus* V-KAPPA (IGKV4-59*01 -IGKJ4*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; (228-228'':231-231'')-bisdisulfide dimer

amatuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MSLN (mésotéline, facteur de potentialisation du pré-pro-mégacaryocyte, facteur de potentialisation des mégacaryocytes, MPF, CAK1)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV1-37*01 - (IGHD)-IGHJ2*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-213')-disulfure avec la chaîne légère kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-59*01 -IGKJ4*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (228-228'':231-231'')-bisdisulfure

amatuximab

inmunoglobulina G1-kappa, anti-[MSLN de *Homo sapiens* (mesotelina, factor de potenciación del pre-pro-megacariocito, factor de potenciación de megacariocitos, MPF, CAK1)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV1-37*01 - (IGHD)-IGHJ2*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-213')-disulfuro con la cadena ligera kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-59*01 -IGKJ4*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada			
QVQLQQSGPE	LEKPGASVKI	SCKASGYSFT	GYTMNWKQS
ITPYNGASSY	NQKFRGKATL	TVDKSSSTAY	MDLLSLTSED
YDGRGFDYWG	SGTPVTVSSA	STKGPSVFPL	APSSKSTSGG
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVVTV
ICNVNHHKPSN	TKVDKKVEPK	SCDKHTTCTP	CPAPELLGGP
DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK
YTLPPSRDEL	TKNQVSLTCL	VKGFPYPSDIA	VEWESNGQPE
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ
Light chain / Chaîne légère / Cadena ligera			
DIELTQSPAI	MSASPGKEVT	MTCASASSVS	YMHWYQQKSG
SKLASGVPR	FSGSGSGNSY	SLTISSVEAE	DDATYYCQOW
TKVEIKRTVA	APSVFIFFPS	DEQLKSGTAS	VVCLLNNFYF
NALQSGNSQE	SVTEQDSKDS	TYSLSSLTLL	SKADYEKHKV
SSPVTKSFNR	GEC		
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro			
Intra-H	22-96	146-202	263-323
	22"-96"	146"-202"	263"-323"
Intra-L	23'-87'	133'-193'	
	23'''-87'''	133'''-193'''	
Inter-H-L	222-213'	222"-213"	
Inter-H-H	228-228"	231-231"	
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación			
299, 299"			

arbaclofenum
arbaclofen



(3*R*)-4-amino-3-(4-chlorophenyl)butanoic acid

arbaclofène

(-)-acide (3*R*)-4-amino-3-(4-chlorophényl)butanoïque

arbaclofeno

ácido (3*R*)-4-amino-3-(4-clorofenil)butanoico



asfotasum alfa #
asfotase alfa

tissue-nonspecific alkaline phosphatase-IgG₁ fusion protein;
human tissue-nonspecific isozyme alkaline phosphatase (AP-TNAP, EC=3.1.3.1) fusion protein with leucyl-lysyl-human immunoglobulin G1 Fc region {(6-15)-H-CH₂-CH₃ of IGHG1*03} fusion protein with aspartyl-isoleucyl-deca(aspartic acid), dimer (493-493':496-496')-bisdisulfide

asfotase alfa

protéine de fusion phosphatase alcaline humaine isozyme tissulaire non-spécifique-IgG₁;
phosphatase alcaline humaine isozyme tissulaire non-spécifique (AP-TNAP, EC=3.1.3.1) protéine de fusion avec la leucyl-lysyl-région Fc {(6-15)-H-CH₂-CH₃ de l'IGHG1*03} de l'immunoglobuline G1 humaine protéine de fusion avec l'aspartyl-isoleucyl-déca(acide aspartique), (493-493':496-496')-bisdisulfure du dimère

asfotasa alfa

proteína de fusión fosfatasa alcalina humana isozima tisular inespecífica-IgG1;
fosfatasa alcalina humana isozima tisular inespecífica (AP-TNAP, EC=3.1.3.1) proteína de fusión con la leucil-lisil-región Fc {(6-15)-H-CH2-CH3 del IGHG1*03} de la inmunoglobulina G1 humana
proteína de fusión con aspartil-isoleucil-deca(acide aspártico), (493-493':496-496')-bisdisulfuro del dímero

C₇₁₀₈H₁₁₀₀₈N₁₉₆₈O₂₂₀₆S₅₆ (peptide)

Monomer / Monomère / Monómero					
LVPEKEKDPK	YWRDQAQETL	KYALELQKLN	TNVAKNVIMF	LGDMGMVSTV	50
TAARILKGQL	HHNPGEETRL	EMDKFPFVAL	SKTYNTNAQV	PDSAGTATAY	100
LCGVKANEGT	VGVSAAATERS	RCNTTQQNEV	TSILRWAKDA	GKSVGIVITTT	150
RVNHATPSAA	YAHSAADRDWY	SDNEMPPEAL	SQGCKDIAYQ	LMHNIRIDIV	200
IMGGGRKMY	PKNKTDVEYE	SDEKARGTRL	DGLDLVDTWK	SFKPRYKSHH	250
FIWNRTELLT	LDPHNVDYLL	GLFEPGDMQY	ELNRNNVTDP	SLSEMVVVAI	300
QILRKNPKGF	FLLVEGGRID	HGHHEGKAKQ	ALHEAVEMDR	ATGQAGSLTS	350
SEDTLTVVTA	DHSHVFTFGG	YTPRGNSIFG	LAPMLSDTDK	KPFTAILYGN	400
GPGYKVVGGG	RENVSMVDYA	HNHYQAQSAV	PLRHETHGGE	DVAVFSKGP	450
AHLLHGVHEQ	NYVPHVMAYA	ACIGANLGHG	APASSLKDKT	HTCPPCPAPE	500
LLGGPSVFLF	PPKPKDTLMI	SRTPEVTCVV	VDVSHEDPEV	KFNWYVDGVE	550
VHNAKTKPRE	EQYNSTYRVV	SVLTVLHQDW	LNGKEYCKV	SNKALPAPIE	600
KTISKAKGQP	REPQVYTLPP	SREEMTKNQV	SLTCLVKGFY	PSDIAVEWES	650
NGQPFENNYKT	TPPVLDSDGS	FFLYSKLTVD	KSRWQQGNVF	SCSVMEALH	700
NHYTQKSLSL	SPGKDIDDD	DDDDDD			726

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
122-184 122'-184' 472-480 472'-480' 528-588
528'-588' 634-692 634'-692' 493-493' 496-496'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-123 Asn-123' Asn-213 Asn-213' Asn-254 Asn-254'
Asn-286 Asn-286' Asn-413 Asn-413' Asn-564 Asn-564'

atinumabum #
atinumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* RTN4 (reticulon 4, neurite outgrowth inhibitor, NOGO), isoform A], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-441) [*Homo sapiens* VH (IGHV3-7*01 (93.80%) -(IGHD)-IGHJ2*01 T122>S) [8.8.7] (1-114) -IGHG4*01 (115-441)], (128-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01 R123>K) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (220-220':223-223')-bisdisulfide dimer

atinumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* RTN4 (réticulon 4, inhibiteur de la croissance des neurites, NOGO), isoforme A], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-441) [*Homo sapiens* VH (IGHV3-7*01 (93.80%) -(IGHD)-IGHJ2*01 T122>S) [8.8.7] (1-114) -IGHG4*01 (115-441)], (128-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01 R123>K) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (220-220':223-223')-bisdisulfure

atinumab

inmunoglobulina G4-kappa, anti-[RTN4 de *Homo sapiens* (reticulón 4, inhibidor del crecimiento de las neuritas, NOGO), isoforma A], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma4 (1-441) [VH de *Homo sapiens* (IGHV3-7*01 (93.80%) -(IGHD)-IGHJ2*01 T122>S) [8.8.7] (1-114) -IGHG4*01 (115-441)], (128-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01 R123>K) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (220-220':223-223')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	NYWMSWVRQA	PGKGLEWVAT	50
IKQDGSQKNY	VDSVKGRFTI	SRDNAKNSLY	LRLNSLRAED	TAVYYCATEL	100
FDLWGRGSLV	TVSSASTKGP	SVFPLAPCSR	STSESTAALG	CLVKDYFPPEP	150
VTVSWNSGAL	TSGVHTFPAV	LQSSGLYSLS	SVVTVPSSSL	GTKTYTCNVD	200
HKPSNTKVDK	RVESKYGPCC	PSCPAPEFLG	GPSVFLFPPK	PKDTLMISRT	250
PEVTCVVVDV	SQEDPEVQFN	WYVDGVEVHN	AKTKPREEQF	NSTYRVVSVL	300
TVLHQDWLNG	KEYKCKVSNK	GLPSSIEKTI	SKAKGQPREP	QVYTLPPSQE	350
EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTPP	VLDSDGSFFL	400
YSRLTVDKSR	WQEGNVFSCS	VMHEALHNHY	TQKSLSLSLG	K	441

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT	LSLSFGERAT	LSCRASQSVS	SYLAWYQQKP	GQAPRLLIYD	50
ASNRATGIPA	RFSGSGSGTD	FTLTISSELP	EDFAVYQCQQ	RSNWPITFGQ	100
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	141-197	255-315	361-419
	22"-96"	141"-197"	255"-315"	361"-419"
Intra-L	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L	128-214'	128"-214"		
Inter-H-H	220-220"	223-223"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

291, 291"

atopaxarum


atopaxar

2-(5,6-diethoxy-7-fluoro-1-imino-1,3-dihydro-2*H*-isoindol-2-yl)-1-[3-*tert*-butyl-4-methoxy-5-(morpholin-4-yl)phenyl]ethan-1-one

atopaxar

2-(5,6-diéthoxy-7-fluoro-1-imino-1,3-dihydro-2*H*-isoindol-2-yl)-1-[3-*tert*-butyl-4-méthoxy-5-(morpholin-4-yl)phényl]éthanone

atopaxar

2-(5,6-dietoxi-7-fluoro-1-imino-1,3-dihidro-2*H*-isoindol-2-il)-1-[3-*terc*-butil-4-metoxi-5-(morfolin-4-il)fenil]etan-1-onaC₂₉H₃₈FN₃O₅

bisegliptinum


bisegliptin

ethyl 4-({2-[(2*S*,4*S*)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl}amino)bicyclo[2.2.2]octane-1-carboxylate

biségliptine

4-({2-[(2*S*,4*S*)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoéthyl}amino)bicyclo[2.2.2]octane-1-carboxylate d'éthyle

bisegliptina

4-({2-[(2*S*,4*S*)-2-ciano-4-fluoropirrolidin-1-il]-2-oxoetil}amino)biciclo[2.2.2]octano-1-carboxilato de etiloC₁₈H₂₆FN₃O₃

burixaforum

burixafor


(2-{4-[6-amino-2-({[(1*r*,4*r*)-4-({[3-(cyclohexylamino)propyl]amino)methyl]cyclohexyl)methyl]amino}pyrimidin-4-yl]piperazin-1-yl}ethyl)phosphonic acid

burixafor

acide (2-{4-[6-amino-2-({[(1*r*,4*r*)-4-({[3-(cyclohexylamino)propyl]amino)méthyl]cyclohexyl)méthyl]amino}pyrimidin-4-yl]pipérazin-1-yl}éthyl)phosphonique

burixafor

ácido (2-{4-[6-amino-2-({[(1*r*,4*r*)-4-({[3-(ciclohexilamino)propil]amino)metil]ciclohexil]metil]amino}pirimidin-4-il]piperazin-1-il}etil)fosfónico

C₂₇H₅₁N₈O₃P**cadazolidum**

cadazolid


1-cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5*R*)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy)methyl]-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinolin-3-carboxylic acid

cadazolid

acide 1-cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5*R*)-5-(hydroxyméthyl)-2-oxo-1,3-oxazolidin-3-yl]phénoxy)méthyl]-4-hydroxypipéridin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

cadazolid


ácido 1-ciclopropil-6-fluoro-7-[4-({2-fluoro-4-[(5*R*)-5-(hidroximetil)-2-oxo-1,3-oxazolidin-3-il]fenoxi]metil)-4-hidroxi-piperidin-1-il]-4-oxo-1,4-dihidroquinolin-3-carboxílico

C₂₉H₂₉F₂N₃O₈**carlumabum #**

carlumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CCL2 (chemokine (C-C motif) ligand 2, C-C motif chemokine 2, monocyte chemoattractant protein-1, MCP-1, monocyte chemotactic and activating factor, MCAF, small inducible cytokine A2, SCYA2, HC11)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV1-69*01 (99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)), (222-216')-disulfide with kappa light chain (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01 [7.3.10] (1'-109') -IGKC*01 (110'-216'))]; (228-228":231-231")-bisdisulfide dimer

carlumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> CCL2 (chimiokine (C-C motif) ligand 2, C-C motif chimiokine 2, protéine 1 chimioattractante du monocyte, MCP-1, facteur activateur et chimiotactique du monocyte, MCAF, SCYA2, HC11)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-449) [<i>Homo sapiens</i> VH (IGHV1-69*01 (99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)), (222-216')-disulfure avec la chaîne légère kappa (1'-216') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10] (1'-109') -IGKC*01 (110'-216'))]; dimère (228-228'':231-231'')-bisdisulfure																																																																																																																		
carlumab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> CCL2 (quimiokina (C-C motif) ligando 2, C-C motif quimiokina 2, proteína 1 quimiotáctica de monocito, MCP-1, factor activador y quimiotático de monocito, MCAF, SCYA2, HC11)], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma1 (1-449) [<i>Homo sapiens</i> VH (IGHV1-69*01 (99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)), (222-216')-disulfuro con la cadena ligera kappa (1'-216') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10] (1'-109') -IGKC*01 (110'-216'))]; dímero (228-228'':231-231'')-bisdisulfuro																																																																																																																		
	Heavy chain / Chaîne lourde / Cadena pesada <table><tr><td>QVQLVQSGAE</td><td>VKKPGSSVKV</td><td>SCKASGGTFS</td><td>SYGISWVRQA</td><td>PGQGLEWMGG</td><td>50</td></tr><tr><td>IIPIFGTANY</td><td>AQKFQGRVTI</td><td>TADESTSTAY</td><td>MELSSLRSED</td><td>TAVVYCARVD</td><td>100</td></tr><tr><td>GIYGELDFWG</td><td>QGTILVTVSSA</td><td>STKGPSVFPL</td><td>APSSKSTSGG</td><td>TAALGCLVKD</td><td>150</td></tr><tr><td>YFPEPVTISW</td><td>NSGALTSGVH</td><td>TTPAVLQSSG</td><td>LYSLSSVTV</td><td>PSSSLGTQTY</td><td>200</td></tr><tr><td>ICNVNHHKPSN</td><td>TKVDKKVEPK</td><td>SCDKTHTCPP</td><td>CPAPELLGGP</td><td>SVFLFPPKPK</td><td>250</td></tr><tr><td>DTLMISRTPE</td><td>VTCVVVDVSH</td><td>EDPEVKFNWY</td><td>VDGVEVHNAK</td><td>TKPREEQYNS</td><td>300</td></tr><tr><td>TYRVVSVLTV</td><td>LHQDWLNGKE</td><td>YKCKVSNKAL</td><td>PAPIEKTISK</td><td>AKGQPREPQV</td><td>350</td></tr><tr><td>YTLPPSRDEL</td><td>TKNQVSLTCL</td><td>VKGFPYSDIA</td><td>VEWESNGQPE</td><td>NNYKTPPV</td><td>400</td></tr><tr><td>DSDGSFFLYS</td><td>KLTVDKSRWQ</td><td>QGNVFSCSVM</td><td>HEALHNHYTQ</td><td>KSLSLSPGK</td><td>449</td></tr></table> Light chain / Chaîne légère / Cadena ligera <table><tr><td>EIVLTQSPAT</td><td>LSLSPGERAT</td><td>LSCRASQSVS</td><td>DAYLAWYQQK</td><td>PGQAPRLLIY</td><td>50</td></tr><tr><td>DASSRATGVP</td><td>ARFSGSGSGT</td><td>DFTLTISSE</td><td>PEDFAVYYCH</td><td>QYIQLHSFTF</td><td>100</td></tr><tr><td>GQGTKVEIKR</td><td>TVAAPSVFIF</td><td>PPSDEQLKSG</td><td>TASVVCLLNN</td><td>FYPREAKVQW</td><td>150</td></tr><tr><td>KVDNALQSGN</td><td>SQESVTEQDS</td><td>KDSTYLSST</td><td>LTLSKADYEK</td><td>HKVYACEVTH</td><td>200</td></tr><tr><td>QGLSSPVTKS</td><td>FNRGEC</td><td></td><td></td><td></td><td>216</td></tr></table> Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro <table><tr><td>Intra-H</td><td>22-96</td><td>146-202</td><td>263-323</td><td>369-427</td></tr><tr><td></td><td>22"-96"</td><td>146"-202"</td><td>263"-323"</td><td>369"-427"</td></tr><tr><td>Intra-L</td><td>23'-89'</td><td>136'-196'</td><td></td><td></td></tr><tr><td></td><td>23'''-89'''</td><td>136'''-196'''</td><td></td><td></td></tr><tr><td>Inter-H-L</td><td>222-216'</td><td>222"-216"</td><td></td><td></td></tr><tr><td>Inter-H-H</td><td>228-228"</td><td>231-231"</td><td></td><td></td></tr></table> N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 299, 299"	QVQLVQSGAE	VKKPGSSVKV	SCKASGGTFS	SYGISWVRQA	PGQGLEWMGG	50	IIPIFGTANY	AQKFQGRVTI	TADESTSTAY	MELSSLRSED	TAVVYCARVD	100	GIYGELDFWG	QGTILVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150	YFPEPVTISW	NSGALTSGVH	TTPAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200	ICNVNHHKPSN	TKVDKKVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	250	DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300	TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350	YTLPPSRDEL	TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTPPV	400	DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449	EIVLTQSPAT	LSLSPGERAT	LSCRASQSVS	DAYLAWYQQK	PGQAPRLLIY	50	DASSRATGVP	ARFSGSGSGT	DFTLTISSE	PEDFAVYYCH	QYIQLHSFTF	100	GQGTKVEIKR	TVAAPSVFIF	PPSDEQLKSG	TASVVCLLNN	FYPREAKVQW	150	KVDNALQSGN	SQESVTEQDS	KDSTYLSST	LTLSKADYEK	HKVYACEVTH	200	QGLSSPVTKS	FNRGEC				216	Intra-H	22-96	146-202	263-323	369-427		22"-96"	146"-202"	263"-323"	369"-427"	Intra-L	23'-89'	136'-196'				23'''-89'''	136'''-196'''			Inter-H-L	222-216'	222"-216"			Inter-H-H	228-228"	231-231"		
QVQLVQSGAE	VKKPGSSVKV	SCKASGGTFS	SYGISWVRQA	PGQGLEWMGG	50																																																																																																														
IIPIFGTANY	AQKFQGRVTI	TADESTSTAY	MELSSLRSED	TAVVYCARVD	100																																																																																																														
GIYGELDFWG	QGTILVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150																																																																																																														
YFPEPVTISW	NSGALTSGVH	TTPAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200																																																																																																														
ICNVNHHKPSN	TKVDKKVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	250																																																																																																														
DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300																																																																																																														
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350																																																																																																														
YTLPPSRDEL	TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTPPV	400																																																																																																														
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449																																																																																																														
EIVLTQSPAT	LSLSPGERAT	LSCRASQSVS	DAYLAWYQQK	PGQAPRLLIY	50																																																																																																														
DASSRATGVP	ARFSGSGSGT	DFTLTISSE	PEDFAVYYCH	QYIQLHSFTF	100																																																																																																														
GQGTKVEIKR	TVAAPSVFIF	PPSDEQLKSG	TASVVCLLNN	FYPREAKVQW	150																																																																																																														
KVDNALQSGN	SQESVTEQDS	KDSTYLSST	LTLSKADYEK	HKVYACEVTH	200																																																																																																														
QGLSSPVTKS	FNRGEC				216																																																																																																														
Intra-H	22-96	146-202	263-323	369-427																																																																																																															
	22"-96"	146"-202"	263"-323"	369"-427"																																																																																																															
Intra-L	23'-89'	136'-196'																																																																																																																	
	23'''-89'''	136'''-196'''																																																																																																																	
Inter-H-L	222-216'	222"-216"																																																																																																																	
Inter-H-H	228-228"	231-231"																																																																																																																	
cenisertibum																																																																																																																			
cenisertib	(1 <i>S</i> ,2 <i>S</i> ,3 <i>R</i> ,4 <i>R</i>)-3-[[5-fluoro-2-({3-methyl-4-(4-methylpiperazin-1-yl)phenyl}amino)pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide																																																																																																																		
cénisertib	(1 <i>S</i> ,2 <i>S</i> ,3 <i>R</i> ,4 <i>R</i>)-3-[[5-fluoro-2-{{3-méthyl-4-(4-méthylpipérazin-1-yl)phényl}amino}pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ène-2-carboxamide																																																																																																																		
cenisertib	(1 <i>S</i> ,2 <i>S</i> ,3 <i>R</i> ,4 <i>R</i>)-3-[[5-fluoro-2-({3-metil-4-(4-metilpiperazin-1-il)fenil}amino)pirimidin-4-il]amino]biciclo[2.2.1]hept-5-eno-2-carboxamida																																																																																																																		

$C_{24}H_{30}FN_7O$ **crolibulinum**


crolibulin

(4*R*)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene-3-carbonitrile

crolibuline

(4*R*)-2,7,8-triamino-4-(3-bromo-4,5-diméthoxyphényl)-4*H*-chromène-3-carbonitrile

crolibulina

(4*R*)-2,7,8-triamino-4-(3-bromo-4,5-dimetoxifenil)-4*H*-cromeno-3-carbonitrilo $C_{18}H_{17}BrN_4O_3$ **darexabanum**


darexaban

N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide

darexaban

N-[2-hydroxy-6-(4-méthoxybenzamido)phényl]-4-(4-méthyl-1,4-diazépan-1-yl)benzamide

darexabán

N-[2-hidroxí-6-(4-metoxibenzamido)fenil]-4-(4-metil-1,4-diazepan-1-il)benzamida $C_{27}H_{30}N_4O_4$ 

delamanidum


delamanid

(2*R*)-2-methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-*b*][1,3]oxazole

délamanid

(2*R*)-2-méthyl-6-nitro-2-[(4-{4-[4-(trifluorométhoxy)phénoxy]pipéridin-1-yl}phénoxy)méthyl]-2,3-dihydroimidazo[2,1-*b*]oxazole

delamanid

(2*R*)-2-metil-6-nitro-2-[(4-{4-[4-(trifluorometoksi)fenoksi]piperidin-1-il}fenoksi)metil]-2,3-dihidroimidazo[2,1-*b*][1,3]oxazolC₂₅H₂₅F₃N₄O₆**edivoxetinum**


edivoxetine

(1*R*)-2-(5-fluoro-2-methoxyphenyl)-1-[(2*S*)-morpholin-2-yl]-1-(oxan-4-yl)ethan-1-ol

édivoxétine

(1*R*)-2-(5-fluoro-2-méthoxyphényl)-1-[(2*S*)-morpholin-2-yl]-1-(oxan-4-yl)éthan-1-ol

edivoxetina

(1*R*)-2-(5-fluoro-2-metoxifenil)-1-[(2*S*)-morfolin-2-il]-1-(oxan-4-il)etan-1-olC₁₈H₂₆FNO₄**efinaconazolum**


efinaconazole

(2*R*,3*R*)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1*H*-1,2,4-triazin-1-yl)butan-2-ol

éfinaconazole

(2*R*,3*R*)-2-(2,4-difluorophényl)-3-(4-méthylènepipéridin-1-yl)-1-(1*H*-1,2,4-triazol-1-yl)butan-2-ol

efinaconazol

(2*R*,3*R*)-2-(2,4-difluorofenil)-3-(4-metilenopiperidin-1-il)-1-(1*H*-1,2,4-triazin-1-il)butan-2-olC₁₈H₂₂F₂N₄O

egaptivonum pegolum
egaptivon pegol


a pegylated aptamer which binds von Willebrand factor;
5'-O-{{[6-(carboxyamino)hexyl]hydroxyphosphoryl}-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidyl-(3'→5')-2'-O-methylcytidyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylcytidyl-(3'→5')-2'-O-methylcytidyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidyl-(3'→5')-2'-O-methyl-P-thioguanlyl-(3'→5')-thymidyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidyl-(3'→3')-thymidine, carbamate ester with monomethyl ether of polyethylene glycol (20 kDa)

egaptivon pégol

aptamère pégylé qui se lie au facteur de von Willebrand;
ester carbamique entre l'éther monométhylique du polyéthylèneglycol (macrogol 20 kDa) et le 5'-O-{{[6-(carboxyamino)hexyl]hydroxyphosphoryl}-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylcytidyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-désoxyguanylyl-(3'→5')-2'-désoxycytidyl-(3'→5')-2'-désoxyadénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylcytidyl-(3'→5')-2'-O-méthylcytidyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthylcytidyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylcytidyl-(3'→5')-2'-désoxycytidyl-(3'→5')-2'-O-méthyl-P-thioguanlyl-(3'→5')-thymidyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-désoxycytidyl-(3'→5')-2'-désoxyguanylyl-(3'→5')-2'-désoxyguanylyl-(3'→5')-thymidyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylcytidyl-(3'→5')-2'-désoxycytidyl-(3'→5')-2'-désoxycytidyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-désoxycytidyl-(3'→5')-2'-O-méthyladenylyl-(3'→5')-2'-O-méthylcytidyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylcytidyl-(3'→3')-thymidine

egaptivón pegol

aptámero pegilado que se une al factor de von Willebrand; éster carbámico entre el éter monometílico del polietilenglicol (macrogol 20 kDa) y el 5'-O-[[6-(carboxiamino)hexil]hidroxifosforil]-2'-O-metilguanilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-O-metil-*P*-tioguanilil-(3'→5')-timidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-timidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilcitidilil-(3'→3')-timidina

$$C_{413}H_{546}N_{144}O_{275}P_{40}S \text{ (C}_2\text{H}_4\text{O)}_n$$


elobixibat
elobixibat


[(2*R*)-2-(2-([3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1*H*-1λ⁶,5-benzothiazepin-8-yl]oxy)acetamido)-2-phenylacetamido]acetic acid

élobixibat

acide [(2*R*)-2-(2-([3,3-dibutyl-7-(méthylsulfanyl)-1,1-dioxo-5-phényl-2,3,4,5-tétrahydro-1*H*-1λ⁶,5-benzothiazépin-8-yl]oxy)acétamido)-2-phénylacétamido]acétique

elobixibat

ácido [(2*R*)-2-(2-([3,3-dibutyl-5-fenil-7-(metilsulfanil)-1,1-dioxo-2,3,4,5-tetrahydro-1*H*-1λ⁶,5-benzotiazepin-8-il]oxi)acetamido)-2-fenilacetamido]acético

$$C_{36}H_{45}N_3O_7S_2$$


elsiglutidum

elsiglutide

[2-glycine(A>G),3-glutamic acid(D>E),8-serine(D>S),10-leucine(M>L),11-serine(N>S),16-alanine(N>A),24-alanine(N>A),28-alanine(Q>A)]human glucagon-like peptide 2 (GLP-2) fusion protein with hexalysinamide

elsiglutide

[2-glycine(A>G),3-acide glutamique(D>E),8-sérine(D>S),10-leucine(M>L),11-sérine(N>S),16-alanine(N>A),24-alanine(N>A),28-alanine(Q>A)]peptide 2 semblable au glucagon humain (GLP-2) protéine de fusion avec l'hexalysinamide

elsiglutida

[2-glicina(A>G),3-acide glutámico(D>E), 8-serina(D>S),10-leucina(M>L),11-serina(N>S),16-alanina(N>A),24-alanina(N>A),28-alanina(Q>A)]péptido 2 similar al glucagón humano(GLP-2) proteína de fusión con hexalisinamida

 $C_{196}H_{323}N_{53}O_{56}$

HGEGSFSSSEL STILDALAAR DFIWLIATK ITDKKKKKK 39

Modified residue / Résidu modifié / Residuo modificado
K lysinamide

empagliflozinum

empagliflozin


(1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxolan-3-yl]oxy}phenyl)methyl]phenyl}-D-glucitol

empagliflozine

(1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxolan-3-yl]oxy}]phényl)méthyl]phényl}-D-glucitol

empagliflozina

(1S)-1,5-anhidro-1-C-{4-cloro-3-[(4-{[(3S)-oxolan-3-il]oxi}]fenil)metil]fenil}-D-glucitol

 $C_{23}H_{27}ClO_7$


enavatuzumabum #
enavatuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF12A (tumor necrosis factor receptor superfamily member 12A, fibroblast growth factor (FGF)-inducible 14 kDa protein, Fn14, TNF-like weak inducer of apoptosis (Tweak) receptor, Tweak receptor, TweakR, CD266], humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV3-7*01 (86.70%) -(IGHD)-IGHJ6*01 T123>L (114)) [8.10.10] (1-119) -*Homo sapiens*IGHG1*01 CH3 D12>E (358), L14>M (360) (120-449)], (222-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (84.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC*01 (112'-218')]; (228-228":231-231")-bisdisulfide dimer

énavatuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF12A (membre 12A de la superfamille des récepteurs du facteur de nécrose tumorale, protéine de 14 kDa induite par le facteur de croissance du fibroblaste (FGF), Fn14, TNF-like faible inducteur d'apoptose (Tweak), récepteur de Tweak, CD266], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV3-7*01 (86.70%) -(IGHD)-IGHJ6*01 T123>L (114)) [8.10.10] (1-119) -*Homo sapiens*IGHG1*01 CH3 D12>E (358), L14>M (360) (120-449)], (222-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (84.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC*01 (112'-218')]; dimère (228-228":231-231")-bisdisulfure

enavatuzumab

inmunoglobulina G1-kappa, anti-[TNFRSF12A de *Homo sapiens* (miembro 12A de la superfamilia de receptores del factor de necrosis tumoral, proteína de 14 kDa inducida por el factor de crecimiento de fibroblastos (FGF), Fn14, TNF-like débil inductor de apoptosis (Tweak), receptor de Tweak, CD266], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens*IGHV3-7*01 (86.70%) -(IGHD)-IGHJ6*01 T123>L (114)) [8.10.10] (1-119) -*Homo sapiens*IGHG1*01 CH3 D12>E (358), L14>M (360) (120-449)], (222-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens*IGKV1-39*01 (84.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC*01 (112'-218')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	SYWMSWVRQA	PGKGLEWVAE	50
IRLKSDNYAT	HYAESVKGRF	TISRDDSKNS	LYLQMNSLRA	EDTAVYYCTG	100
YYADAMDYWG	QGLTLVTSSA	STKGPSVFPF	AFSSKSTSGG	TAALGCLVKD	150
YFPEPVTISW	NSGALTSGVH	TFFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDKKVEPK	SCDKTHCTCP	CPAPELLGGP	SVFLFPPKPK	250
DTLMISRTP	ETCVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVVSVLT	LHQDNLNGE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSREEM	TKNQVSLTCL	VKGFPYPSDIA	VEWESNGQPE	NNYKTPPVVL	400
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASVGDRVT	ITCRASQSVS	TSSYSYMHWY	QQKPGKAPKL	50
LIRYASNL	GVPSRFSGSG	SGTDFTLTIS	SLQPEDFATY	YQHSWEIPY	100
TFGGGTKVEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVCLL	NNFYPREAKV	150
QWKVDNALQS	GNQESVTEQ	DSKDYSTYLS	STLTLSKADY	EKHKYACEV	200
THQGLSSPVT	KSFNRGEC				218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-98	146-202	263-323	369-427
	22"-98"	146"-202"	263"-323"	369"-427"
Intra-L	23'-92'	138'-198'		
	23'''-92'''	138'''-198'''		
Inter-H-L	222-218'	222"-218"		
Inter-H-H	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

enokizumabum #
enokizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL9 (interleukin 9, IL-9, T cell growth factor p40)], humanized monoclonal antibody; gamma1 heavy chain (1-452) [humanized VH (*Homo sapiens*IGHV1-69*11 (87.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens*IGHG1*03 (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (83.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; (231-231":234-234")-bisdisulfide dimer

énokizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL9 (interleukine 9, IL-9, facteur de croissance p40 des cellules T)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-452) [VH humanisé (*Homo sapiens*IGHV1-69*11 (87.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens*IGHG1*03 (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (83.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dimère (231-231":234-234")-bisdisulfure

enokizumab

inmunoglobulina G1-kappa, anti-[IL9 de *Homo sapiens* (interleukina 9, IL-9, factor de crecimiento p40 de células T)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-452) [VH humanizada (*Homo sapiens*IGHV1-69*11 (87.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens*IGHG1*03 (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens*IGKV1-39*01 (83.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKKPGSSVKV	SCRASGGTFS	YYWIEWVRQA	PGQGLEWMGE	50
ILPGSGTTNP	NEKFKGRVTI	TADESTSTAY	MELSSSLRSED	TAVYYCARAD	100
YYGSDYVKFD	YWGQGTLLTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL	150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSV	VTVPSSSLGT	200
QTYICNVNHK	PSNTKVDKRV	EPKSCDKTHT	CPPCPAPELL	GGPSVFLFPP	250
KPKDTLMISR	TPEVTCVVVD	VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ	300
YNSTYRVVSV	LTVLHQDWLN	GKEYCKCKVN	KALPAPIEKT	ISKAKGQPRE	350
PQVYTLPPSR	EEMTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTTT	400
PVLDSDSGFF	LYSKLTVDKS	RWQQGNVFSC	SVMHEALHNN	YTQKSLSLSP	450
GK					452

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASVGDRVIT	ITCKASQHVI	THVTWYQQKP	GKAPKLLIYG	50
TSYSYSGVPS	RFGSGSGGTD	FTLTISSLQP	EDFATYYCQQ	FYEYPLTFGG	100
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKKH	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	149-205	266-326	372-430
	22"-96"	149"-205"	266"-326"	372"-430"
Intra-L	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L	225-214'	225"-214'"		
Inter-H-H	231-231"	234-234"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

302, 302"


erteberelum
erteberel

(3a*S*,4*R*,9*bR*)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9*b*-hexahydrocyclopenta[*c*]chromen-8-ol

ertébérel

(3a*S*,4*R*,9*bR*)-4-(4-hydroxyphényl)-1,2,3,3a,4,9*b*-hexahydrocyclopenta[*c*][1]chromén-8-ol

erteberel

(3aS,4*R*,9*bR*)-4-(4-hidroxifenil)-1,2,3,3a,4,9*b*-hexahidrociclopenta[*c*]cromen-8-ol $C_{18}H_{18}O_3$ etrolizumabum #
etrolizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* integrins ITGA4_ITGB7 (integrin alpha4 (CD49d)_beta7, integrin $\alpha 4\beta 7$, lymphocyte Peyer's patch adhesion molecule 1, LPAM-1) and ITGAE_ITGB7 (integrin alphaE (CD103, alphaIEL)_beta7, integrin $\alpha E\beta 7$, HML-1], humanized monoclonal antibody; gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens*IGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -*Homo sapiens*IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-446)], (220-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; (226-226":229-229")-bisdisulfide dimer

étrolizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* intégrines ITGA4_ITGB7 (intégrine alpha4 (CD49d)_bêta7, intégrine $\alpha 4\beta 7$, récepteur d'adressage spécifique des plaques de Peyer, LPAM-1) et ITGAE_ITGB7 (intégrine alphaE (CD103, alphaIEL)_bêta7, intégrine $\alpha E\beta 7$, HML1)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens*IGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -*Homo sapiens*IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-446)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dimère (226-226":229-229")-bisdisulfure

etrolizumab

immunoglobuline G1-kappa, anti-[integrinas ITGA4_ITGB7 de *Homo sapiens* (integrina alfa4 (CD49d)_beta7, integrina $\alpha 4\beta 7$, molécula de adhesión específica de linfocitos de las placas de Peyer, LPAM-1) e ITGAE_ITGB7 (integrina alfaE (CD103, alfaIEL)_beta7, integrina $\alpha E\beta 7$, HML1)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-446) [VH humanizada (*Homo sapiens*IGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -*Homo sapiens*IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-446)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG	LVQPGGSLRL	SCAASGFFIT	NNYWGWRQA	PGKGLEWVG	50
ISYSGSTSYN	PSLKSRTTIS	RDTSKNTFY	QMNSLRAEDT	AVYYCARTGS	100
SGYFDWGGQ	TLVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	ALGCLVKDYF	150
PEPVTVSNN	GALTSVHTF	PAVLQSSGLY	SLSSVTVPS	SSLGTQTYIC	200
NVNHKPSNTK	VDKKVEPKSC	DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	300
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	350
LPSPREEMTK	NQVSLTCLVK	GFYPDSIAVE	WESNGQPENN	YKTTTPVLD	400
DGSFFLYSKL	TVDKSRWQGG	NVFSCVMHE	ALHNHYTQKS	LSLSPG	446

Light chain / Chaîne légère / Cadena ligera


DIQMTQSPSS	LSASVGDRVT	ITCRASESVD	DLHWYQQK	GKAPKLLIKY	50
ASQISISGVP	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQ	GNSLPNTFGQ	100
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLNNFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKK	VYACEVTHQG	200
LSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-95	144-200	261-321	367-425
	22"-95"	144"-200"	261"-321"	367"-425"
Intra-L	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L	220-214'	220"-214"		
Inter-H-H	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

297, 297"

florbenazinium (¹⁸F)
florbenazine (¹⁸F)(2*R*,3*R*,11*bR*)-9-(3-[¹⁸F]fluoropropoxy)-10-methoxy-3-(2-methylpropyl)-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrido[2,1-*a*]isoquinolin-2-olflorbénazine (¹⁸F)(2*R*,3*R*,11*bR*)-9-(3-[¹⁸F]fluoropropoxy)-10-méthoxy-3-(2-méthylpropyl)-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrido[2,1-*a*]isoquinoléin-2-olflorbenazina (¹⁸F)(2*R*,3*R*,11*bR*)-9-(3-[¹⁸F]fluoropropoxi)-3-(2-metilpropil)-10-metoxi-1,3,4,6,7,11*b*-hexahidro-2*H*-pirido[2,1-*a*]isoquinolin-2-olC₂₁H₃₂ ¹⁸FNO₃**forigerimodum**
forigerimodO^{3,140}-phosphono(human U1 small nuclear ribonucleoprotein 70 kDa (snRNP70))-(131-151)-peptide

forigérimod

O^{3,140}-phosphono(petite ribonucléoprotéine nucléaire U1 humaine de 70 kDa (snRNP70))-(131-151)-peptide

forigerimod


O^{3,140}-fosfono(pequeña ribonucleoproteína nuclear U1 humana de 70 kDa (snRNP70))-(131-151)-péptido

C₁₁₇H₁₈₁N₃₄O₃₂PS

RIHMOVYSKRS GKPRGYAFIE Y

21

Modified residues / Résidus modifiés / Residuos modificados

**fulranumabum #**

fulranumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF)], *Homo sapiens* monoclonal antibody;

gamma2 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-48*02 (92.90%) -(IGHD)-IGHJ4*01 [8.8.16] (1-123) -IGHG2*01 (124-449)], (137-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (225-225'':226-226':229-229'':232-232'')]-tetrakisdisulfide dimer

fulranumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* NGF (facteur de croissance du nerf, facteur de croissance du nerf polypeptide bêta, NGFB, bêta-NGF)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-449) [*Homo sapiens* VH (IGHV3-48*02 (92.90%) -(IGHD)-IGHJ4*01 [8.8.16] (1-123) -IGHG2*01 (124-449)], (137-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225'':226-226':229-229'':232-232'')]-tétrakisdisulfure

fulranumab

inmunoglobulina G2-kappa, anti-[NGF de *Homo sapiens* (factor de crecimiento de nervios, factor de crecimiento de nervios polipéptido beta, NGFB, beta-NGF)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma2 (1-449) [*Homo sapiens* VH (IGHV3-48*02 (92.90%) -(IGHD)-IGHJ4*01 [8.8.16] (1-123) -IGHG2*01 (124-449)], (137-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-225'':226-226':229-229'':232-232'')]-tetraakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

EVQLVESGGG LVQPFGSLRL SCAASGFTLR SYSMNWVRQA PGKGLEWVS 50
ISRSSHTIFY ADSVKGRFTI SRDNAKNSLY LQMDSLRDED TAMYYCARVY 100
SSGWHVSDYF DYWGQGILVT VSSASTKGPS VFPLAPCSRST SESTAALGC 150
LVKDYFFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSNFG 200
TQTYTCNVDH KPSNTKVDKT VERKCCVECP PCPAPPVAGP SVFLFPFKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TFRVVSIVLT VHQQDLNKGK YKCKVSNKGL PAPIETISK TKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPML 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449

```

Light chain / Chaîne légère / Cadena ligera

```

AIQLTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYD 50
ASSLESGVPS RFGSGSGGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200
LSPFVTKSFN RGE 214

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-96 150-206 263-323 369-427
        22"-96" 150"-206" 263"-323" 369"-427"
Intra-L 23'-88" 134'-194"
        23'"-88'" 134'"-194'"
Inter-H-L 137-214' 137"-214"
Inter-H-H 225-225" 226-226" 229-229" 232-232"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

gaxilosum

gaxilose


4-O-β-D-galactopyranosyl-D-xylose

gaxilose

4-O-β-D-galactopyranosyl-D-xylose

gaxilosa

4-O-β-D-galactopiranosil-D-xilosa

C₁₁H₂₀O₁₀**gevokizumabum #**

gevokizumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* IL1B (interleukin 1 beta, 1L1F2, IL-1B)], humanized monoclonal antibody; gamma2 heavy chain (1-445) [humanized VH (*Homo sapiens*IGHV2-5*10 (72.70%) -(IGHD)-IGHJ5*01) [10.7.12] (1-120) -*Homo sapiens*IGHG2*02 CH3 K130>del (121-445)], (134-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (82.10%) -IGKJ1*01 V124>L (104')) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; (222-222":223-223":226-226":229-229")-tetrakisdisulfide dimer

gévakizumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* IL1B (interleukine 1 bêta, 1L1F2, IL-1B)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-445) [VH humanisé (*Homo sapiens*IGHV2-5*10 (72.70%) -(IGHD)-IGHJ5*01) [10.7.12] (1-120) -*Homo sapiens*IGHG2*02 CH3 K130>del (121-445)], (134-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (82.10%) -IGKJ1*01 V124>L (104')) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dimère (222-222":223-223":226-226":229-229")-tétrakisdisulfure

gevokizumab

inmunoglobulina G2-kappa, anti-[IL1B de *Homo sapiens* (interleukina 1 beta, 1L1F2, IL-1B)], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-445) [VH humanizada (*Homo sapiens*IGHV2-5*10 (72.70%) -(IGHD)-IGHJ5*01) [10.7.12] (1-120) -*Homo sapiens*IGHG2*02 CH3 K130>del (121-445)], (134-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-39*01 (82.10%) -IGKJ1*01 V124>L (104')) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dímero (222-222":223-223":226-226":229-229")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQESGPG LVKPSQTLISL TCSFSGFSL TSGMGVGWIR QPSGKGLEWL 50
 AHIWWDGDES YNPSLKSRLT ISKDTSKNQV SLKITSVTAA DTAVYFCARN 100
 RYDPPWFVDW GQGLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VTSSNFGTQT 200
 YTCNVDHKPS NTKVDKTVR KCCVECPPCP APPVAGPSVF LFPPKPKDTL 250
 MISRTPEVTC VVVDVSHEDP EVQFNWYVDG MEVHNAKTKP REEQFNSTFR 300
 VVSVLTVVHQ DWLNGKEYKC KVSNGKLPAP IEKTISKTKG QPREPQVYTL 350
 PPSREEMTKN QVSLTCLVKG FYPQDIQAEW ESNQGPENNY KTTTPMLDSD 400
 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG 445

Light chain / Chaîne légère / Cadena ligera

DIQMTQSTSS LSASVGDRTV ITCRASQDIS NYLSWYQQKP GKAVKLLIYY 50
 TSKLHSGVPS RFGSGSGSDT YTLTISSLQQ EDFATYFCLQ GKMLPWTFGQ 100
 GTKLEIKRTV AAPSVPFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-97 147-203 260-320 366-424
 22"-97" 147"-203" 260"-320" 366"-424"
 Intra-L 23'-88' 134'-194'
 23'''-88''' 134'''-194'''
 Inter-H-L 134-214' 134"-214"
 Inter-H-H 222-222" 223-223" 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
296, 296"

granotapidium
 granotapide

diethyl 2-({2-[3-(dimethylcarbamoyl)-4-{4'-(trifluoromethyl)-
 [1,1'-biphenyl]-2-carboxamido}phenyl]acetyloxy)methyl}-
 2-phenylpropanedioate


granotapide

2-[(2-[3-(diméthylcarbamoyl)-4-{{4'-(trifluorométhyl)-[1,1'-biphényl]-
 2-yl-carboxamido}phényl]acétyl}oxy)méthyl]-2-phénylpropanedioate
 de diéthyle

granotapida

2-({2-[3-(dimetilcarbamoil)-4-{4'-(trifluorometil)-[1,1'-bifenil]-
 2-carboxamido}fenil]acetiloxi}metil)-2-fenilpropanodioato de dietilo

$C_{39}H_{37}F_3N_2O_8$



icrucumabum #
 icrucumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor)], *Homo sapiens* monoclonal antibody;
 gamma1 heavy chain (1-456) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*01 [8.8.19] (1-126)-IGHG1*03 (127-456)], (229-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ4*01 [7.3.9] (1'-108') -IGKC1*01 (109'-215'))]; (235-235":238-238")-bisdisulfide dimer

icrucumab immunoglobuline G1 kappa, anti-[*Homo sapiens* FLT1 (tyrosine kinase 1 apparentée au fms, récepteur 1 du facteur de croissance endothélial vasculaire, VEGFR-1, VEGFR, FLT, FRT, récepteur du facteur de perméabilité vasculaire)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-456) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*01 [8.8.19] (1-126) -IGHG1*03 (127-456)), (229-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ4*01 [7.3.9] (1'-108') -IGKC1*01 (109'-215'))]; dimère (235-235":238-238")-bisdisulfure

icrucumab inmuno globulina G1 kappa, anti-[*Homo sapiens* FLT1 (tirocin kinasa 1 emparentada con el fms, receptor 1 del factor de crecimiento endotelial vascular, VEGFR-1, VEGFR, FLT, FRT, receptor del factor de permeabilidad vascular)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-456) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*01 [8.8.19] (1-126) -IGHG1*03 (127-456)), (229-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ4*01 [7.3.9] (1'-108') -IGKC1*01 (109'-215'))]; dímero (235-235":238-238")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QAQVVESGGG	VVQSGRSLRL	SCAASGF	AFS	SYGMHWVRQA	PGKGLEWVAV	50
INVDGSNKYY	ADSVRCRFTI	SRDENSE	TLY	LQMNSLRAED	TAVYYCARDH	100
YGSGVHHYFY	YGLDVWGQGT	TVTSSASTK	GPSVFPLAPS	SKSTSGGTAA		150
LGCLVKDYFP	EPVTVSWNSG	ALTSQVHTFP	AVLQSSGLYS	LSSVTVTPSS		200
SLGTQTYICN	VNHKPSNTKV	DKRVEPKSCD	KTHTCPPCPA	PELLGGPSVF		250
LFPPKPKDTL	MISRTPEVTC	VVVDVSHEDP	EVKFNWYVDG	VEVHNARTKP		300
REEQYNSTYR	VVSVLTVLHQ	DWLNGKEYKC	KVSNKALPAP	IEKTIISKAKG		350
QPREPQVYTL	PPSREEMTKN	QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY		400
KTTPPVLDSD	GSFFLYSKLT	VDKSRWQQGN	VFSCSVMHEA	LHNHYTQKSL		450
SLSPGK						456

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	SSYLAWYQQK	PGQAPRLLIY		50
GASSRATGIP	DRFSGSGSGT	DFTLTISRLE	PEDFAVYYCQ	QYGSSTPLTFG		100
GGTKVEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLNNF	YPREAKVQWK		150
VDNALQSGNS	QESVTEQDSK	DSTYLSSTL	TLSKADYKEH	KVYACEVTHQ		200
GLSSPVTKSF	NRGEC					215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	153-209	270-330	376-434
	22"-96"	153"-209"	270"-330"	376"-434"
Intra-L	23'-89'	135'-195'		
	23'''-89'''	135'''-195'''		
Inter-H-L	229-215'	229"-215"		
Inter-H-H	235-235"	238-238"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación



306, 306"

irosustatum

irosustat 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate

irosustat sulfamate de 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromèn-3-yle

irosustat sulfamato de 6-oxo-6,7,8,9,10,11-hexahidrociclohepta[c]cromen-3-ilo

**ivacaftorum**

ivacaftor



N-(2,4-di-*tert*-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

ivacaftor

N-[2,4-di-*tert*-butyl-5-hydroxyphényl]-4-oxo-1,4-dihydroquinoléine-3-carboxamide

ivacaftor

N-(2,4-di-*terc*-butil-5-hidroxifenil)-4-oxo-1,4-dihidroquinolina-3-carboxamida

**ixazomibum**

ixazomib


{{(1*R*)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic acid

ixazomib

acide [(1*R*)-1-[[*N*-(2,5-dichlorobenzoyl)glycyl]amino]-3-méthylbutyl]boronique

ixazomib

acido {(1*R*)-1-[(2,5-diclorobenzamido)acetamido]-3-metilbutil}borónico

**lenvatinibum**

lenvatinib


4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide

lenvatinib

4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phénoxy}-7-méthoxyquinoléine-6-carboxamide

lenvatinib

4-{3-cloro-4-[(ciclopropilcarbamoil)amino]fenoxi}-7-metoxiquinolina-6-carboxamida

$C_{21}H_{19}ClN_4O_4$ **letaxabanum**


letaxaban

1-({1-[(2*S*)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl]piperidin-4-yl}tetrahydropyrimidin-2(1*H*)-one

létaxaban

1-({1-[(2*S*)-3-[(6-chloronaphthalén-2-yl)sulfonyl]-2-hydroxypropanoyl]pipéridin-4-yl}tétrahydropyrimidin-2(1*H*)-one

letaxabán

1-({1-[(2*S*)-3-[(6-cloronaftalen-2-il)sulfonyl]-2-hidroxiopropanoil]piperidin-4-il}tetrahidropirimidin-2(1*H*)-ona $C_{22}H_{26}ClN_3O_5S$ **letermovirum**


letermovir

(4*S*)-2-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid

létermovir

acide {(4*S*)-8-fluoro-2-[4-(3-méthoxyphényl)pipérazin-1-yl]-3-[2-méthoxy-5-(trifluorométhyl)phényl]-3,4-dihydroquinazolin-4-yl}acétique

letermovir

ácido (4*S*)-2-[8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético $C_{29}H_{26}F_4N_4O_4$ 

levoglucosum

levoglucose


L-glucose

lévoglucose

L-glucose

levoglucosa

L-glucosa

 $C_6H_{12}O_6$ **linsitinibum**


linsitinib

(1*s*,3*r*)-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-*a*]pyrazin-3-yl]-1-methylcyclobutan-1-ol

linsitinib

(1*s*,3*r*)-3-[8-amino-1-(2-phénylquinoléin-7-yl)imidazo[1,5-*a*]pyrazin-3-yl]-1-méthylcyclobutan-1-ol

linsitinib

(1*s*,3*r*)-3-[8-amino-1-(2-fenilquinolin-7-il)imidazo[1,5-*a*]pirazin-3-il]-1-metilciclobutan-1-ol $C_{26}H_{23}N_5O$ **luseogliflozinum**


luseogliflozin

(2*S*,3*R*,4*R*,5*S*,6*R*)-2-{5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl}-6-(hydroxymethyl)thiane-3,4,5-triol

luséogliflozine

(2*S*,3*R*,4*R*,5*S*,6*R*)-2-{5-[(4-éthoxyphényl)méthyl]-2-méthoxy-4-méthylphényl}-6-(hydroxyméthyl)thiane-3,4,5-triol

luseogliflozina

(2*S*,3*R*,4*R*,5*S*,6*R*)-2-{5-[(4-etoxifenil)metil]-4-metilfenil-2-metoksi}-6-(hidroximetil)tiano-3,4,5-triol $C_{23}H_{30}O_6S$ 

lusutrombopagum


lusutrombopag

(2*E*)-3-{2,6-dichloro-4-[(4-{3-[(1*S*)-1-(hexyloxy)ethyl]-2-methoxyphenyl}-1,3-thiazol-2-yl)carbamoyl]phenyl}-2-methylprop-2-enoic acid

lusutrombopag

acide (2*E*)-3-{2,6-dichloro-4-[(4-{3-[(1*S*)-1-(hexyloxy)éthyl]-2-méthoxyphényl}-1,3-thiazol-2-yl)carbamoyl]phényl}-2-méthylprop-2-énoïque

lusutrombopag

ácido (2*E*)-3-{2,6-dicloro-4-[(4-{3-[(1*S*)-1-(hexiloxi)etil]-2-metoxifenil}-1,3-tiazol-2-il)carbamoil]fenil}-2-metilprop-2-enoicoC₂₉H₃₂Cl₂N₂O₅S**mavoglurantum**


mavoglurant

methyl (3*aR*,4*S*,7*aR*)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]octahydro-1*H*-indole-1-carboxylate

mavoglurant

(3*aR*,4*S*,7*aR*)-4-hydroxy-4-[2-(3-méthylphényl)éthynyl]octahydro-1*H*-indole-1-carboxylate de méthyle

mavoglurant

(3*aR*,4*S*,7*aR*)-4-hidroxi-4-[2-(3-metilfenil)etiniil]octahidro-1*H*-indol-1-carboxilato de metilC₁₉H₂₃NO₃**mogamulizumabum #**

mogamulizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CCR4 (chemokine (C-C motif) receptor 4, CC chemokine receptor 4, CCR-4, CKR4, k5-5, CD194)], humanized monoclonal antibody; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*01 (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2-29*02 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer

mogamulizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CCR4 (récepteur 4 de chimiokine (C-C motif), récepteur 4 de chimiokine CC, CCR-4, CKR4, k5-5, CD194)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*01 (120-449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2-29*02 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure

mogamulizumab

immunoglobulina G1-kappa, anti-[CCR4 de *Homo sapiens* (receptor 4 de quimiokina (C-C motif), receptor 4 de quimiokina CC, CCR-4, CKR4, k5-5, CD194)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens*IGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2-29*02 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGD	LVQFGRSLRL	SCAASGFIFS	NYGMSWVRQA	PGKGLEWVAT	50
ISSASTYSY	PDSVKGRFTI	SRDNAKNSLY	LQMNSLRVED	TALYYCGRHS	100
DGNFAFGYW	QGTSLTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFPVLQSSG	LYSLSSVVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDKKVEPK	SCDKTHCTCP	CPAPELLGGP	SVFLFPPKPK	250
DTLMISRTPE	VTGVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQVNS	300
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSRDEL	TKNQVSLTCL	VKGIFYPSDIA	VEWESNGQPE	NNYKTTTPVL	400
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449

Light chain / Chaîne légère / Cadena ligera

DVLMTQSP	LPVTPGEPAS	ISCRSSRNIV	HINGDTYLEW	YLQKPGQSPQ	50
LLIYKVSNR	SGVPDRFSGS	GSGETDFTLKI	SRVEAEDVGV	YYCFQGSLLP	100
WTFGQGTKE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVIVCL	LNNFYPREAK	150
VQWVKVDNAL	SGNSQESVTE	QDSKDYSTSL	SSTLTLSKAD	YEKHKVYACE	200
VTHQGLSSPV	TKSFNRGEC				219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L	23'-93'	139'-199'		
	23'''-93'''	139'''-199'''		
Inter-H-L	222-219'	222"-219"		
Inter-H-H	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

namilumabum

namilumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CSF2 (*Homo sapiens* colony stimulating factor 2 (granulocyte-macrophage), granulocyte-macrophage colony stimulating factor, GM-CSF)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV1-2*02 (89.80%) -(IGHD)-IGHJ4*01 L123>M (114)) [8.8.12] (1-119) - IGHG1*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (88.40%) - IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

namilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CSF2 (*Homo sapiens* facteur 2 stimulant de colonies (granulocyte-macrophage), facteur stimulant des colonies de granulocytes et macrophages, GM-CSF)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV1-2*02 (89.80%) -(IGHD)-IGHJ4*01 L123>M (114)) [8.8.12] (1-119) - IGHG1*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (88.40%) - IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

namilumab

inmunoglobulina G1-kappa, anti-[CSF2 de *Homo sapiens* (*Homo sapiens* factor 2 estimulante de colonias (granulocito-macrófago), factor estimulante de colonias de granulocitos y macrófagos, GM-CSF)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV1-2*02 (89.80%) -(IGHD)-IGHJ4*01 L123>M (114)) [8.8.12] (1-119) -IGHG1*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (88.40%) -IGKJ4*01 [6.3.9] (1'-107') -IGKC*01 (108'-214'))]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKAFGYPFT DYLLHWVRQA PGQGLEWVGW 50
LNPYSGDTNY AQKFQGRVTM TRDTSISTAY MELSRRLRSD TAVYYCTRTT 100
LISVYFDYWG QGTMVTVSSA STKGPSVFPF APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPVQLQSSG LYSLSVTVV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHCTCP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTP E VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS VSASVGDRV TACRASQNI R NILNWYQQR GKAPQLLIYA 50
ASNLQSGVPS RFSGSGSGTD FTLTINSIQP EDFATYYCQ SYSMPTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"

Intra-L 23'-88' 134'-194'

23'''-88''' 134'''-194'''

Inter-H-L 222-214' 222"-214"

Inter-H-H 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

naronapridum

naronapride

(3*R*)-1-azabicyclo[2.2.2]octan-3-yl 6-[(3*S*,4*R*)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl]hexanoate


naronapride

6-[(3*S*,4*R*)-4-(4-amino-5-chloro-2-méthoxybenzamido)-3-méthoxypipéridin-1-yl]hexanoate de (3*R*)-1-azabicyclo[2.2.2]oct-3-yl

naronaprida

6-[(3*S*,4*R*)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il]hexanoato de (3*R*)-1-azabicyclo[2.2.2]octan-3-ilo

C₂₇H₄₁ClN₄O₅



onartuzumabum #
onartuzumab

immunoglobulin G1-kappa monovalent Fab-Fc, anti-[*Homo sapiens* MET (met proto-oncogene, hepatocyte growth factor receptor, HGFR, scatter factor receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-Met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368), L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens*IGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens*IGKC*01 (114'-220')], (228-6"-231-9")-bisdisulfide with truncated gamma1 chain consisting of partial hinge-CH2-CH3 (1"-227") [*Homo sapiens*IGHG1*01 hinge 6-15(1"-10")-CH2(11"-120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W (146")]

onartuzumab

immunoglobuline G1-kappa monovalent Fab-Fc, anti-[*Homo sapiens* MET (proto-oncogène met, récepteur du facteur de croissance hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368), L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (*Homo sapiens*IGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens*IGKC*01 (114'-220')], (228-6"-231-9")-bisdisulfure avec la chaîne gamma1 tronquée comprenant charnière partielle-CH2-CH3 (1"-227") [*Homo sapiens*IGHG1*01 charnière 6-15(1"-10")-CH2(11"-120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W (146")]

onartuzumab

inmunoglobulina G1-kappa monovalente Fab-Fc, anti-[*Homo sapiens* MET (protooncogén met, receptor del factor de crecimiento hepatocitario, HGFR, receptor del factor de dispersión, receptor de l'HGF/SF, receptor de tirosina proteína-kinasa c-Met, carcinoma papilar de células renales 2, RCCP2)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens*IGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368), L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizada (*Homo sapiens*IGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens*IGKC*01 (114'-220')], (228-6"-231-9")-bisdisulfuro con la cadena gamma1 truncada que comprende parte de la bisagra-CH2-CH3 (1"-227") [*Homo sapiens*IGHG1*01 bisagra 6-15(1"-10")-CH2(11"-120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W (146")]

Heavy chain / Chaîne lourde / Cadena pesada (H)

```

EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYWLHWVRQA PGKGLEWVGM 50
IDPSNSDTRF NPNFKDRFTI SADTSKNTAY LQMNSLRAED TAVYYCATYR 100
SYVTPLDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPVAVLQSSG LYSLSVVTV PSSSLGTQTY 200
ICNVNKKPSN TKVDKKVEPK SCDKTHTCP CPAPPELLGGP SVFLFPPKPK 250
DTLMISRTPF VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LQDOWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
DSDGSFFLVS KLTVDKSRWQ QGNVFSCSVN HEALHNHYTQ KSLSLSPGK 449

```

Light chain / Chaîne légère / Cadena ligera (L)

```

DIQMTQSPSS LSASVGDRVIT ITCKSSQSLT YTSSQKNYLA WYQQKPGKAP 50
KLLIYWASTR ESGVPSRFSG SGSGTDFTLT ISSLPEDFA TYQCQQYYAY 100
PWTFGGQTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC 220

```

Hinge-CH2-CH3 / Charnière-CH2-CH3 / Bisagra-CH2-CH3 (H')

```

DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 50
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDOWLNGKEYK 100
CKVSNKALPA PIEKTISKAK GQPREPQVYT LPSPREEMTK NQVSLWCLVK 150
GFYPSDIAVE WESNGQPENN YKTTTPVLDS DGSFFLYSKL TVDKSRWQGG 200
NVFSCSVME ALHNHYTQKS LSLSPGK 227

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-96 146-202 263-323 369-427
Intra-H' 41"-101" 147"-205"
Intra-L 23'-94' 140'-200'
Inter-H-L 222-220'
Inter-H-H" 228-6" 231-9"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 77" unglycosylated as expressed in *Escherichia coli*

orteronelem

orteronelem


6-[(7*S*)-7-hydroxy-6,7-dihydro-5*H*-pyrrolo[1,2-*c*]imidazol-7-yl]-*N*-methylinaphthalene-2-carboxamide

ortéronel

6-[(7*S*)-7-hydroxy-6,7-dihydro-5*H*-pyrrolo[1,2-*c*]imidazol-7-yl]-*N*-méthylinaphtalène-2-carboxamide

orteronelem

6-[(7*S*)-7-hidroxi-6,7-dihidro-5*H*-pirrolo[1,2-*c*]imidazol-7-il]-*N*-metilnaftaleno-2-carboxamida

 $C_{18}H_{17}N_3O_2$
**pacritinibum**

pacritinib



((2*E*,16*E*)-11-[2-(pyrrolidin-1-yl)ethoxy]-14,19-dioxo-5,7,27-triazatetracyclo[19.3.1.1^{2,6}.1^{8,12}]heptacos-1(25),2,4,6,8,10,12(26),16,21,23-decaene

pacritinib

(16*E*)-11-[2-(pyrrolidin-1-yl)éthoxy]-14,19-dioxo-5,7,27-triazatétracyclo[19.3.1.1^{2,6}.1^{8,12}]heptacos-1(24),2,4,6,8,10,12(26),16,21(25),22-décaène

pacritinib

((2*E*,16*E*)-11-[2-(pirrolidin-1-il)etoxi]-14,19-dioxo-5,7,27-triazatetraciclo[19.3.1.1^{2,6}.1^{8,12}]heptacos-1(25),2,4,6,8,10,12(26),16,21,23-decaeno

**plecanatidum**

plecanatide


[3-glutamic acid(D>E)]human uroguanylin (UGN)

plécanatide

[3-acide glutamique(D>E)]uroguanyline humaine (UGN)

plecanatida

[3-ácido glutámico(D>E)]uroguanilina humana (UGN)



NDECELCVNV ACTGCL

16

Disulfide bridges location / Position des ponts disulfure/ Posiciones de los puentes disulfuros
4-12 7-15**pomaglumetadum methionilum**



pomaglumedad methionil

(1*R*,4*S*,5*S*,6*S*)-4-(L-methionylamino)-2,2-dioxo-2λ⁶-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid

pomaglumétad méthionil

acide (1*R*,4*S*,5*S*,6*S*)-4-(L-méthionylamino)-2,2-dioxo-2λ⁶-thiabicyclo[3.1.0]hexane-4,6-dicarboxylique

pomaglumedad metionilo

ácido (1*R*,4*S*,5*S*,6*S*)-4-(L-metionilamino)-2,2-dioxo-2λ⁶-tiabíciclo[3.1.0]hexano-4,6-dicarboxílico**ponatinibum**

ponatinib



3-[2-(imidazo[1,2-*b*]pyridazin-3-yl)ethynyl]-4-methyl-*N*-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide

ponatinib

3-[2-(imidazo[1,2-*b*]pyridazin-3-yl)éthynyl]-4-méthyl-*N*-{4-[(4-méthylpipérazin-1-yl)méthyl]-3-(trifluorométhyl)phényl}benzamide

ponatinib

3-[2-(imidazo[1,2-*b*]piridazin-3-il)etinizil]-4-metil-*N*-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida



ponesimabum #
ponesimab

immunoglobulin G2-kappa, anti-[*Homo sapiens* amyloid beta (A beta) peptide Aβ40], humanized monoclonal antibody; gamma2 heavy chain (1-442) [humanized VH (*Homo sapiens*IGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -*Homo sapiens*IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)], (130-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2-30*01 (89.00%) -IGKJ5*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; (218-218":219-219":222-222":225-225")-tetrakisdisulfide dimer

ponesimab

immunoglobuline G2-kappa, anti-[*Homo sapiens* peptide amyloïde bêta (A bêta) Aβ40], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-442) [VH humanisé (*Homo sapiens*IGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -*Homo sapiens*IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)], (130-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2-30*01 (89.00%) -IGKJ5*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dimère (218-218":219-219":222-222":225-225")-tétrakisdisulfure

ponesimab

inmunoglobulina G2-kappa, anti-[péptido amiloide beta de *Homo sapiens* (A beta) Aβ40], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-442) [VH humanizada (*Homo sapiens*IGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -*Homo sapiens*IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)], (130-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens*IGKV2-30*01 (89.00%) -IGKJ5*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dímer (218-218":219-219":222-222":225-225")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGASVKV SCKASGYYTE AYYIHWVRQA PGQGLEWMGR 50
IDPATGNTKY APRLDQDRVTM TRDTSTSTVY MELSSLRSRD TAVYYCASLY 100
SLPVYWGQGT TVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS NFGTQTYTCN 200
VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRVVS 300
LTVVHGDWLN GKEYKCKVSN KGLPSSIEKT ISKTKGQPRE PQVYTLPPSR 350
EEMTKNQVSL TCLVKGFPYS DIAVEWESNG QPENNYKTP PMLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTQKSLSLSP GK 442

```

Light chain / Chaîne légère / Cadena ligera

```

DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL YSDAKTYLNW FQQRPGQSPR 50
RLIYQISRLD PGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQGTHYP 100
VLFQGGTRLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDYSTSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNREGC 219

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-96 143-199 256-316 362-420
         22"-96" 143"-199" 256"-316" 362"-420"
Intra-L 23'-93' 139'-199'
         23"'-93"" 139""-199""
Inter-H-L 130-219' 130"-219""
Inter-H-H 218-218" 219-219" 222-222" 225-225"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
292, 292"

pracinostat


pracinostat

(2*E*)-3-{2-butyl-1-[2-(dimethylamino)ethyl]-1*H*-benzimidazol-5-yl}-*N*-hydroxyprop-2-enamide

pracinostat

(2*E*)-3-{2-butyl-1-[2-(diéthylamino)éthyl]-1*H*-benzimidazol-5-yl}-*N*-hydroxyprop-2-énamide

pracinostat

(2*E*)-3-{2-butyl-1-[2-(dimetilamino)etil]-1*H*-bencimidazol-5-il}-*N*-hidroxyprop-2-enamidaC₂₀H₃₀N₄O₂**quizartinibum**


quizartinib

1-(5-*tert*-butyl-1,2-oxazol-3-yl)-3-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-*b*][1,3]benzothiazol-2-yl}phenyl)urea

quizartinib

N-[5-*tert*-butyl-1,2-oxazol-3-yl]-*N'*-(4-{7-[2-(morpholin-4-yl)éthoxy]imidazo[2,1-*b*][1,3]benzothiazol-2-yl}phényl)urée

quizartinib

1-(5-*terc*-butil-1,2-oxazol-3-il)-3-(4-{7-[2-(morfolin-4-il)etoxi]imidazo[2,1-*b*][1,3]benzotiazol-2-il}fenil)ureaC₂₉H₃₂N₆O₄S**radotinibum**


radotinib

4-methyl-*N*-[3-(4-methyl-1*H*-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyrazin-2-yl)pyrimidin-2-yl]amino}benzamide

radotinib

4-méthyl-*N*-[3-(4-méthyl-1*H*-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-{[4-(pyrazin-2-yl)pyrimidin-2-yl]amino}benzamide

radotinib

4-metil-*N*-[3-(4-metil-1*H*-imidazol-1-il)-5-(trifluorometil)fenil]-3-{[4-(pirazin-2-il)pirimidin-2-il]amino}benzamidaC₂₇H₂₁F₃N₈O

radretumabum #

radretumab

immunoglobulin scFv-CH dimer, anti-[*Homo sapiens* fibronectin extra domain B (ED-B)], *Homo sapiens* monoclonal antibody fragment dimer of single chain (scFv) fused with the IGHE CH4; scFv-CH (1-357) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) - (IGHD)-IGHJ4*01) [8.8.14] (1-116)-12-mer linker (117-128)- *Homo sapiens* V-KAPPA (IGKV3-20*01 (94.80%) -IGKJ1*01) [7.3.9] (129-236)-5-mer linker (237-241)- *Homo sapiens* IGHE*01 CH4 (242-349)-8-mer linker (350-357)]; (357:357') disulfide dimer

radrétumab

immunoglobuline scFv-CH dimère, anti-[*Homo sapiens* extra domaine B (ED-B) de la fibronectine], *Homo sapiens* anticorps monoclonal fragment dimère de scFv fusionné au CH4 de l'IGHE; scFv-CH (1-357) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) - (IGHD)-IGHJ4*01) [8.8.14] (1-116)-12-mer linker (117-128)- *Homo sapiens* V-KAPPA (IGKV3-20*01 (94.80%) -IGKJ1*01) [7.3.9] (129-236)-5-mer linker (237-241)- *Homo sapiens* IGHE*01 CH4 (242-349)-8-mer linker (350-357)]; dimère (357:357')

radretumab

inmunoglobulina scFv-CH dímero, anti-[*Homo sapiens* extra dominio B (ED-B) de la fibronectina], fragmento de anticuerpo monoclonal de *Homo sapiens* dímero de scFv fusionado con el CH4 del IGHE; scFv-CH (1-357) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) - (IGHD)-IGHJ4*01) [8.8.14] (1-116)-dodecámero de conexión (117-128)- *Homo sapiens* V-KAPPA (IGKV3-20*01 (94.80%) -IGKJ1*01) [7.3.9] (129-236)-pentámero de conexión (237-241)- *Homo sapiens* IGHE*01 CH4 (242-349)-octámero de conexión (350-357)]; dímero (357:357') disulfuro

scFv-CH chain / Chaîne scFv-CH / Cadena scFv-CH

```
EVQLLES GGG LVQPGGSLRL SCAASGFTFS SFSMSWVRQA PGKGLEWVSS 50
ISGSSGTTY ADQVKGRTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPF 100
PYFDYWGQGT LVTVSSGDGS SGGSGGASEI VLTQSPGTLT LSPGERATLS 150
CRASQSVSSS FLAWYQQKPG QAPRLLIYYA SSRATGIPDR FSGSGSGTDF 200
TLTISRLEPE DFAVYYCQQT GRIPPTFGQG TKVEIKSGGS GGPRAAPEVY 250
AFATPEWPGS RDKRTLACLI QNFMPEDISV QWLHNEVQLP DARHSTTQPR 300
KTKGSGGFVF SRLEVTRAEW EQKDEFICRA VHEAASPSQT VQRAVSVNPE 350
SSRRGGC
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain 22-96 151-217 268-328

22'-96' 151'-217' 268'-328'

Inter-chain 357-357'

selurampanelum

selurampanel


N-[6-(1-methyl-1*H*-pyrazol-5-yl)-7-(propan-2-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]methanesulfonamide

sélurampanel

N-[6-(1-méthyl-1*H*-pyrazol-5-yl)-7-(propan-2-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]méthanesulfonamide

selurampanel

N-[6-(1-metil-1*H*-pirazol-5-il)-7-(propan-2-il)-2,4-dioxo-1,4-dihidroquinazolin-3(2*H*)-il]metanosulfonamida

C₁₆H₁₉N₅O₄S

setipiprantum

setipiprant


[8-fluoro-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl]acetic acid

sétipiprant

acide 2-[8-fluoro-2-(naphthalén-1-ylcarbonyl)-1,2,3,4-tétrahydro-5H-pyrido[4,3-b]indol-5-yl]acétique

setipiprant

ácido {8-fluoro-2-(naftalen-1-carbonil)-1,2,3,4-tetrahidro-5H-pirido[4,3-b]indol-5-il}acético

 $C_{24}H_{19}FN_2O_3$ **silmitasertibum**

silmitasertib


5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic acid

silmitasertib

acide 5-[(3-chlorophényl)amino]benzo[c][2,6]naphtyridine-8-carboxylique

silmitasertib

ácido 5-[(3-clorofenil)amino]benzo[c][2,6]naftiridina-8-carboxílico

 $C_{19}H_{12}ClN_3O_2$ **simoctocogum alfa #**

simoctocog alfa

B-domain deleted human coagulation factor VIII;
 [749-glutamine,750-alanine-751-tyrosine-753-tyrosine-754-arginine-755-arginine-756-glycine]human coagulation factor VIIIa heavy chain-(1-756)-peptide (containing F5/8 type A 1 and A 2 domains)
 fusion protein with human coagulation factor VIIIa light chain, glycosylated

simoctocog alfa

facteur VIII de coagulation humain dont le domaine B a été supprimé;
 [749-glutamine,750-alanine-751-tyrosine-753-tyrosine-754-arginine-755-arginine-756-glycine]chaîne lourde du facteur VIIIa de coagulation humain-(1-756)-peptide (contenant les domaines F5/8 type A 1 and A 2) protéine de fusion avec la chaîne légère du facteur VIIIa de coagulation humain glycosylé

simoctocog alfa

factor VIII de coagulación humano cuyo dominio B se ha suprimido;
 [749-glutamina,750-alanina-751-tirosina-753-tirosina-754-arginina-755-arginina-756-glicina]cadena pesada del factor VIIIa de coagulación humano-(1-756)-péptido (contiene los dominios F5/8 tipo A 1 y A 2) proteína de fusión con la cadena ligera del factor VIIIa de coagulación humano glicosilado

C₇₄₅₉H₁₁₃₃₈N₁₉₉₂O₂₁₈₈S₆₈ (peptide)

ATRRYYLGAVALSWDYMQSDLGELPVDARFPPRVPKSFPPNTSVVYKKTLL50
 FVEFTDHLFENIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHA100
 VGVSVWKASEGAEYDDQTSQREKEDDKVFPGGSHYVWQVLKENGPMASD150
 PLCLTYSYLSHVDLVKDLNSGLIGALLVCRGSLAKEKTQTLHKFILLFA200
 VFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHR250
 KSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPTFTLTAQTLL300
 MDLGQFLFLFC HISSHQHDMGEAYVKVDSCP EEPQLRMKNNEAEYDDDDL350
 TDSEMDVVRFDNDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVL400
 APDDRSYKSYLNNNGPQRIGRKYKKVRFMA YTDFTFKTREATQHESGILG450
 PLYGEVGDTLIIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKD500
 FPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSFVNMERDLASGLIGP550
 LLICYKESVDQRGNQIMSDKRNVLFSVFDENRSWYLTENIQRFLENPAG600
 VQLEDPEFQASNIMHSINGYVFDLSQLSVC LHEVAYWYILSIGAQDTPLS650
 VFSGYTFFKHKMVEDTLTLFPFSGETVFM SMENPGLWILGCHNSDFRNR700
 GMTALLKVSSCDKNTGDYEDISAYLSKNNAIEPRSFQNSRHHQ750
 YRYYRGEITRTLLQSDQEEIDYDDTISVEMKKEDFDIYDENQSPRSFQ800
 KKTRHYFIAAVERLWDYGMS SSPHVLNRNRAQSGSVPPQFKKVVFQEFDTGS850
 FTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISY900
 EEDQROGAEP RKNFVKPNETKTYFWKVQHHMAPTKDEFDC KAWAYFSDVD950
 LEKDVHSGLI GPLLVCNTLNPAGHQVTVQEFALFFTFDETKSWYFT1000
 ENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQIRW1050
 YLLSMGNSNENIHSIHFSGHVFTVRKKEEYK MALYNLYPGVFETVEMLSK1100
 AGIWRVECLI GEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQ1150
 YGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGKTKGARQK1200
 FSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSGIRKHNINFP1250
 PIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITA1300
 SSYFTNMFATWSPSKARLHLQGRSNAWRPVNNPKWLQVDFQKTMKVTG1350
 VTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVVFQGNQDSFTP1400
 VVNSLDPPLLTRYLRHPQS WVHQIALRMEVLGCEAQDLY1440

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 153-179 248-329 528-554 630-711 940-966 1007-1011 1129-1277 1282-1434

Sulfated residues (Y) / Résidus sulfatés (Y) / Reioduos sulfatados (Y)
 Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-772 Tyr-788

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-41 Asn-239 Asn-918 Asn-1226

talimogenum laherparepvecum #
 talimogene laherparepvec

recombinant replicating *Herpes simplex* type -1 virus vector, with ICP47 and both copies of ICP34.5 genes deleted, expressing human granulocyte macrophage colony stimulating factor (hGM-CSF) in the ICP34.5 loci

talimogène laherparépvec

vecteur viral *Herpes simplex* type 1 répliquant avec délétion du gène ICP47 et des deux copies du gène ICP34.5, exprimant le facteur humain de développement des polynucléaires et des macrophages (hGM-CSF) dans les loci ICP34.5

talimogén laherparepvec

vector virus del *Herpes simplex* tipo-1 replicante recombinante con delección del gen ICP47 y las dos copias del gen ICP34.5, que expresa el factor humano estimulante de colonias de granulocitos y macrófagos (hGM-CSF) in los loci ICP34.5

tedizolidum
 tedizolid



(5*R*)-3-{3-fluoro-4-[6-(2-methyl-2*H*-tetrazol-5-yl)pyridin-3-yl]phenyl}-5-(hydroxymethyl)-1,3-oxazolidin-2-one

tédizolid

(5*R*)-3-{3-fluoro-4-[6-(2-méthyl-2*H*-tétrazol-5-yl)pyridin-3-yl]phényl}-5-(hydroxyméthyl)-1,3-oxazolidin-2-one

tedizolid

(5*R*)-3-{3-fluoro-4-[6-(2-metil-2*H*-tetrazol-5-il)piridin-3-il]fenil}-5-(hidroximetil)-1,3-oxazolidina-2-ona

**telotristatum**

telotristat


4-(2-amino-6-((1*R*)-1-[4-chloro-2-(3-methyl-1*H*-pyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-*L*-phenylalanine

télotristat

4-(2-amino-6-((1*R*)-1-[4-chloro-2-(3-méthyl-1*H*-pyrazol-1-yl)phényl]-2,2,2-trifluoroéthoxy)pyrimidin-4-yl)-*L*-phénylalanine

telotristat

4-(2-amino-6-((1*R*)-1-[4-cloro-2-(3-metil-1*H*-pirazol-1-il)fenil]-2,2,2-trifluoroetoxi)pirimidin-4-il)-*L*-fenilalanina

**tregalizumabum #**

tregalizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD4 (T cell surface antigen T4/Leu-3, p55)], humanized monoclonal antibody; gamma1 heavy chain (1-454) [humanized VH (*Homo sapiens*IGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-124) -*Homo sapiens*IGHG1*01 (125-454)], (227-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens*IGKV4-1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC*01 (112'-218')]; (233-233":236-236")-bisdisulfide dimer

trégalizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD4 (antigène de surface T4/Leu-3 de cellule T, p55)], anticorps monoclonal humanisé; chaîne lourde gamma1(1-454) [VH humanisé (*Homo sapiens*IGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-124) -*Homo sapiens*IGHG1*01 (125-454)], (227-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens*IGKV4-1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC*01 (112'-218')]; dimère (233-233":236-236")-bisdisulfure

tregalizumab

inmunoglobulina G1-kappa, anti-[CD4 de *Homo sapiens* (antígeno de superficie T4/Leu-3 de célula T, p55)], anticuerpo monoclonal humanizado; cadena pesada gamma1(1-454) [VH humanizada (*Homo sapiens*IGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-124) -*Homo sapiens*IGHG1*01 (125-454)], (227-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens*IGKV4-1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC*01 (112'-218')]; dimero (233-233":236-236")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
EEQLVESGGG LVKPGGSLRL SCAASGFSFS DCRMWLRQA PGKLEWIGV 50
ISVKSENYGA NYAESVRGRF TISRDDSKNT VYLQMNLSKT EDTAVVYCSA 100
SYRYRDVGAW FAYWGQGLTV TVSSASTKGP SVFPLAPSSK STSGGTAAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPCPCAPE LLGGPSVFLF 250
FPKPKDTLMI SRTPEVTCVV VDVSHEDFEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK 454

Light chain / Chaîne légère / Cadena ligera
DIVMTQSPDS LAVSLGERAT INCRASKSVS TSGYSYIYWY QQKPGQPPKL 50
LIYLAILES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQHSRELPW 100
TFGQGTQVEI KRTVAAPSVF IFPPSDEQLK SGTSASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLT STLTLKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-98 151-207 268-328 374-432
22"-98" 151"-207" 268"-328" 374"-432"
Intra-L 23'-92' 138'-198'
23'''-92''' 138'''-198'''
Inter-H-L 227'-218' 227"-218"
Inter-H-H 233-233" 236-236"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
304, 304"

turoctocogum alfa #
turoctocog alfa

human coagulation factor VIII-(1-750)-(1638-2332)-peptide,
glycosylated

turoctocog alfa

facteur VIII de coagulation humain-(1-750)-(1638-2332)-peptide
glycosylé

turoctocog alfa

factor VIII de coagulación humano-(1-750)-(1638-2332)-péptido
glicosilado

C₇₄₈₀H₁₁₃₇₉N₁₉₉₉O₂₁₉₄S₆₈ (peptide)

ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSPFF NTSVVYKKTLL 50
FVEFTDHLFN IAKPRPFWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKAEE GAEDDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISF ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDMG EAYVVKVDSCE EEPQLRMKN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSPFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKQS YLNNGPQRIQ RYKVKVRFMA YTDFTFKTRE AIQHEGSLIG 450
PLLYGEVGDQ LLIIIFKNQAS RPYNIYPHGI TDVRPLYSRRL LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSFVNM ERLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYL TEN IQRFLNPAQ 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDPLS 650
VFFSGYTFKH KMVEDTLTL PFFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYIE DSYEDISAYL LSKNNAIEPR SFSQNSRHPS 750
QNPPVLKRHQ REITRTTLQS DQEEIDYDDT ISVEMKKEDF DIYDEDENQS 800
PRSFQKKTRH YFIAAVERLW DYGMSSSPHV LRNRAQSGSV PQFKKVVFQE 850
FTDGSFTQPL YRGELNEHLG LLGPYIRAEV EDNIMVTFRN QASRPYSFYS 900
SLISYEEDQR QGAEPKKNFV KPNETKTYFW KVQHMAPTK DEFDCAWAY 950
FSDVDLEKDV HSLIGLPLLV CHTNTLNPAP GRQVTVQEFAL FFTIFDETK 1000
SWYFTENMER NCRAPCNIQM EDPTFKENYR FHAINGYIMD TLPGLVMAQD 1050
QRIRWYLLSM GSNENIHSIH FSGHVFTVRK KEEYKMALYN LYPGVFETVE 1100
MLPSKAGIWR VECLIGEHLH AGMSTLFLVY SNKQQTPLGM ASGHIRDFOI 1150
TASGQYGQWA PKLARLHYSG SINAWSTKEP FSWIKVDLLA PMIIHGKTKQ 1200
GARQKQSSLY ISQFIIMYSL DGKKWQTYRG NSTGTLMVFF GNVDSSGIKH 1250
NIFNPPIIAR YIRLHPHYS IRSTLRMELM GCDLNSCSPM LGMESKAISD 1300
AQITASSYFT NMFATWSPSK ARLHLQGRSN AWRPQVNNPK EWLQVDFQKT 1350
MKVTGVTQGG VKSLTSMYV KEFLISSQD GHQWTLFFQN GKVKVFQGNQ 1400
DSFTFVVNSL DPPLLTRYLR IHPQSWVHQI ALRMEVLGCE AQDLY 1445

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 945-971 1012-1016 1134-1282 1287-1439

Sulfated residues (Y) / Résidus sulfatés (Y) / Residuos sulfatados(Y)
Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-777 Tyr-793

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-41 Asn-239 Asn-923 Asn-1231

ublituximabum #

ublituximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, B lymphocyte surface antigen B1, leukocyte surface antigen Leu-16, Bp35, CD20), chimeric monoclonal antibody; gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-12*01 - (IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-213')-disulfide with kappa light chain (1'-213') [*Mus musculus* V-KAPPA (IGKV4-72*01 -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; (227-227'':230-230'')-bisdisulfide dimer

ublituximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A avec 4 transmembrane regions, antigène de surface B1 des lymphocytes B, antigène de surface Leu-16 des leucocytes, Bp35, CD20), anticorps monoclonal chimérique; chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-12*01 - (IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-213')-disulfure avec la chaîne légère kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-72*01 -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (227-227'':230-230'')-bisdisulfure

ublituximab

inmunoglobulina G1-kappa, anti-[MS4A1 de *Homo sapiens* (miembro 1 de la subfamilia A con 4 regiones , transmembrana , antígeno de superficie B1 de linfocitos B, antígeno de superficie Leu-16 de leucocitos, Bp35, CD20), anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-448) [*Mus musculus* VH(IGHV1-12*01 - (IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-72*01 -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QAYLQQSGAE	LVRPGASVKM	SCKASGYTFT	SYNMHWVKQT	PRQGLEWIGG	50
IYPGNGDTSY	NQKFKGKATL	TVGKSSSTAY	MQLSSLTSED	SAVYFCARYD	100
YNYAMDYWGQ	GTSVTVSSAS	TKGPSVFPLA	PSSKSTSGGT	AALGCLVKDY	150
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSSLGTQTYI	200
CNVNHKPSNT	KVDKKVEPKS	CDKTHTCPPC	PAPELLGGPS	VFLFPPKPKD	250
TLMISRTPEV	TCVVVDVSHE	DPEVKFNWYV	DGVEVHNAKT	KPREEQYNST	300
YRVVSVLTVL	HQDWLNGKEY	KCKVSNKALP	APIEKTISKA	KGQPREPQVY	350
TLPPSRDELT	KNQVSLTCLV	KGFYPSDIAV	EWESNGQFEN	NYKTTTPPVL	400
SDGSFPLYSK	LTVDKSRWQQ	GNVFSCSVMH	EALHNNHYTK	SLSLSPGK	448

Light chain / Chaîne légère / Cadena ligera

QIVLSQSPAI	LSASPGKEVT	MTCRASSSVS	YMHYQQKPG	SSPKPWIYAT	50
SNLASGVPAR	FSGSGSGTSS	SFTISRVEAE	DAATYYCQW	TFNPPTFGGG	100
TRLEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD	150
NALQSGNSQE	SVTEQDSKDS	TYSLSTLTTL	SKADYEKHKV	YACEVTHQGL	200
SSPVTKSFNR	GEC				213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	145-201	262-322	368-426
	22"-96"	145"-201"	262"-322"	368"-426"
Intra-L	23'-87'	133'-193'		
	23'''-87'''	133'''-193'''		
Inter-H-L	221-213'	221"-213'''		
Inter-H-H	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

298, 298"

urelumabum #

urelumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* TNFRSF9 (tumor necrosis factor receptor superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-448) [*Homo sapiens* VH (IGHV4-34*01 (92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 hinge S10>P (229) (122-448)], (135-216')-disulfide with kappa light chain (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; (227-227'':230-230'')-bisdisulfide dimer

urélumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* TNFRSF9 (membre 9 de la superfamille des récepteurs du facteur de nécrose tumorale, 4-1BB, antigène ILA de lymphocyte T, CD137)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-448) [*Homo sapiens* VH (IGHV4-34*01 (92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 charnière S10>P (229) (122-448)], (135-216')-disulfure avec la chaîne légère kappa (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; dimère (227-227'':230-230'')-bisdisulfure

urelumab

inmunoglobulina G4-kappa, anti-[TNFRSF9 de *Homo sapiens* (miembro 9 de la superfamilia de receptores del factor de necrosis tumoral, 4-1BB, antígeno ILA de linfocito T, CD137)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma4 (1-448) [*Homo sapiens* VH (IGHV4-34*01 (92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 bisagra S10>P (229) (122-448)], (135-216')-disulfuro con la cadena ligera kappa (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLQQWAG LLKPSETLSL TCAVYGGSF S GYYWSWIRQS PEKGLEWIGE 50
INHGQVVTYN PSLESRTVIS VDTSKNQFSL KLSSVTAADT AVYYCARDYG 100
PGNYDWYFDL WGRGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSV TVPSSSLGSK 200
TYTCNVDPKPT SNTKVDKRV SKYGPPCPPC PAPEFLGGPS VFLFPFKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTIVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQFEN NYKTPPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGLK 448

```

Light chain / Chaîne légère / Cadena ligera

```

EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKQ GPAPRLLIYD 50
ASNRRATGIPA RFGSGSGGTD FTLTISSLEP EDFAVYYCQQ RSNWPPALTF 100
CGGKVEIKR TVAAPSVEFIF PPSDEQLKSG TASVVCLLNN FYPREKQVQW 150
KVDNALQSGN SQESVTEQDS KDSTYLSLST LTLSKADYEK HKVYACEVTH 200
QGLSSPVTKS FNRGEC 216

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-95 148-204 262-322 368-426
        22"-95" 148"-204" 262"-322" 368"-426"
Intra-L 23'-88' 136'-196'
        23'"-88'" 136'"-196'"
Inter-H-L 135-216' 135"-216'"
Inter-H-H 227-227" 230-230"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298"

usistapidum

usistapide


methyl (2S)-2-phenyl-2-[4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido)phenyl]piperidin-1-yl]acetate

usistapide

(+)-(2S)-2-phényl-2-[4-([4'-(trifluorométhyl)-[1,1'-biphényl]-2-yl]carbonyl)amino]phényl]pipéridin-1-yl]acétate de méthyle

usistapida

(2S)-2-fenil-2-[4-(4'-(trifluorometil)-[1,1'-bifenil]-2-carboxamido)fenil]piperidin-1-il]acetato de metilo

C₃₄H₃₁F₃N₂O₃**vesencumabum #**

vesencumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* NRP1 (neuropilin 1, NRP, vascular endothelial cell growth factor 165 receptor, VEGF165 receptor, VEGF165R, CD304) extracellular domain], *Homo sapiens* monoclonal antibody;gamma1 heavy chain (1-453) [*Homo sapiens* VH (IGHV3-23*04 (90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3 D12>E (362), L14>M (364) (124-453)], (226-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (232-232'':235-235'')-bisdisulfide dimer

vésencumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* NRP1 (neuropiline 1, NRP, récepteur de l'isoforme 165 du facteur de croissance des cellules endothéliales vasculaires, récepteur du VEGF165, VEGF165R, CD304) domaine extracellulaire], *Homo sapiens* anticorps monoclonal;chaîne lourde gamma1 (1-453) [*Homo sapiens* VH (IGHV3-23*04 (90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3 D12>E (362), L14>M (364) (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (232-232'':235-235'')-bisdisulfure

vesencumab

inmunoglobulina G1-kappa, anti-[NRP1 de *Homo sapiens* (neuropilina 1, NRP, receptor de la isoforma 165 del factor de crecimiento de células endoteliales vasculares, receptor de VEGF165, VEGF165R, CD304) dominio extracelular], anticuerpo monoclonal de *Homo sapiens*;cadena pesada gamma1 (1-453) [VH de *Homo sapiens* (IGHV3-23*04 (90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3 D12>E (362), L14>M (364) (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (232-232'':235-235'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSQ 50
ISPAGGYTNY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARGE 100
LPYYRMSKVM DVWGQGTIVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLEP 250
PKPKDTLMIS RTPETVCVVV DVSHEDEPKV FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYCKKVS NKALPAPIEK TISKAGGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQFENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTKSLSLS 450
PGK 453

```

Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPSS LSASVGDRVIT ITCRASQYFS SYLAWYQQKP GKAPKLLIYG 50
ASSRASGVPS RFGSGSGTD FTLTISSLQP EDFATYYCQQ YLGSPPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-96 150-206 267-327 373-431
        22"-96" 150"-206" 267"-327" 373"-431"
Intra-L 23'-88' 134'-194'
        23'''-88''' 134'''-194'''
Inter-H-L 226-214' 226"-214"
Inter-H-H 232-232" 235-235"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

303, 303"

vidupiprantum

vidupiprant

{4-[4-(*tert*-butylcarbamoyl)-2-(2-chloro-4-cyclopropylbenzenesulfonamido)phenoxy]-5-chloro-2-fluorophenyl}acetic acid


vidupiprant

acide {4-[4-(*tert*-butylcarbamoyl)-2-(2-chloro-4-cyclopropylbenzenesulfonamido)phénoxy]-5-chloro-2-fluorophényl}acétique

vidupiprant

ácido {4-[4-(*terc*-butilcarbamoil)-2-(2-cloro-4-ciclopropilbencenosulfonamido)fenoxi]-5-cloro-2-fluorofenil}acético

C₂₈H₂₇Cl₂FN₂O₆S

**vosaroxinum**

vosaroxin



7-[(3*S*,4*S*)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

vosaroxine

acide 7-[(3*S*,4*S*)-3-méthoxy-4-(méthylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphtyridine-3-carboxylique

vosaroxina

ácido 7-[(3*S*,4*S*)-4-(metilamino)-3-metoxipirrolidin-1-il]-4-oxo-1-(1,3-tiazol-2-il)-1,4-dihidro-1,8-naftiridina-3-carboxílico



**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Non Proprietary Names (Rec. INN): List 51
Dénominations communes internationales proposées (DCI Rec.): Liste 51
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 51
(WHO Drug Information, Vol. 18, No. 1, 2004)

p. 86 **cantuzumabum mertansinum#**
 cantuzumab mertansine
 cantuzumab mertansine
 cantuzumab mertansina

replace the description and the structure by the following ones
 remplacer la description et la structure par les suivantes
 sustitúyase la descripción y la estructura por las siguientes

immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242)], humanized monoclonal antibody conjugated to maytansinoid DM1;
 gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer; conjugated, on an average of 4 lysyl, to maytansinoid DM1 [*N*²-deacetyl-*N*²-(3-mercapto-1-oxopropyl)-maytansine] via the reducible SPP linker [*N*-succinimidyl 4-(2-pyridyldithio)pentanoate]
 For the *mertansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*"

immunoglobuline G1-kappa, anti-[*Homo sapiens* glycane sialylé de MUC1, associé à des tumeurs (CA242, antigène du cancer 242)], anticorps monoclonal humanisé conjugué au maytansinoïde DM1;
 chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 4 lysyl en moyenne, au maytansinoïde DM1 [*N*²-déacétyl-*N*²-(3-mercapto-1-oxopropyl)-maytansine] via le linker SPP réductible [4-(2-pyridyldithio)pentanoate de *N*-succinimide]
 Pour la partie *mertansine*, veuillez vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*"

inmunoglobulina G1-kappa, anti-[glicano sialilado de MUC1 de *Homo sapiens*, asociado a tumores (CA242, antígeno del cáncer 242)], anticuerpo monoclonal humanizado conjugado con el maitansinoide DM1; cadena pesada (gamma1 (1-449) [VH humanizada (*Homo sapiens*IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens*IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens*IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, por término medio, en 4 grupos lisil, con el maitansinoide DM1 [*N*²-desacetil-*N*²-(3-mercapto-1-oxopropil)-maitansina] mediante el espaciador SPP reducible [4-(2-piridilditio)pentanoato de *N*-succinimidilo]

Para la *mertansina*, por favor, consulten el documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

cantuzumab/ cantuzumab / cantuzumab

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKKPGETVKI	SCKASDYTFT	YYGMNWKQA	PGQGLKWMGW	50
IDTTTGPEPT	AQKFQGRIAF	SLETSASTAY	LQIKSLKSED	TATYFCARRG	100
PYNWYFDVWG	QGTTVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDKKVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPKPKK	250
DTLMISRTP	ETCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVVSVLT	VHQLDNLNGE	YKCKVSNKAL	PAPIETISK	AKGQPREPQV	350
YTLPPSRDEL	TKNQVSLTCL	VKGFPSPDIA	VEWESNGQPE	NNYKTTTPVL	400
DSGDSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALNNHYTQ	KSLSLSPGK	449

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPLS	VPVTPGEPVS	ISCRSSKSL	HSNGNTLYW	FLQRPQGSPQ	50
LLIYRMSNLV	SGVPDRFSGS	GSGETAFTLR	SRVEAEDVGV	YYCLQHLEY	100
FTFGPGTKLE	LKRTVAAPSV	FIFPPSDEQL	KSGTASVCL	LNNFYPREAK	150
VQWVKVDNAL	QSGNSQESVTE	QDSKDSSTYS	LSTLTLSKAD	YEKHKVYACE	200
VTHQGLSSPV	TKSFNRGEC				219


Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L	23'-93'	139'-199'		
	23'''-93'''	139'''-199'''		
Inter-H-L	222-219'	222"-219'''		
Inter-H-H	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

mertansine / mertansine / mertansina



cantuzumab = Ig(NH₂)₄

Recommended International Non Proprietary Names (Rec. INN): List 65
Dénominations communes internationales proposées (DCI Rec.): Liste 65
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 65
(WHO Drug Information, Vol. 25, No. 1, 2011)

p. 84 **samalizumabum #**

samalizumab
samalizumab
samalizumab

replace the description by the following one
remplacer la description par la suivante
sustitúyase la descripción por la siguiente

immunoglobulin G2/4-kappa, anti-[*Homo sapiens* CD200 (OX-2)], humanized monoclonal antibody;
gamma2/4 heavy chain (1-442) [humanized VH (*Homo sapiens*IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T (112), V124>L (113)) [8.8.10] (1-117) - *Homo sapiens*IGHG2*01 CH1-hinge-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-33*01 (81.10%) - IGKJ2*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; (219-219":220-220":223-223":226-226")-tetrakisdisulfide dimer

immunoglobuline G2/4-kappa, anti-[*Homo sapiens* CD200 (OX-2)], anticorps monoclonal humanisé;
chaîne lourde gamma2/4 (1-442) [VH humanisé (*Homo sapiens*IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T (112), V124>L (113)) [8.8.10] (1-117) - *Homo sapiens*IGHG2*01 CH1-charnière-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dimère (219-219":220-220":223-223":226-226")-tétrakisdisulfure

inmunoglobulina G2/4-kappa, anti-[*Homo sapiens* CD200 (OX-2)], anticuerpo monoclonal humanizado;
cadena pesada gamma2/4 (1-442) [humanizado VH (*Homo sapiens*IGHV1-69*01 (73.50%) - (IGHD)-IGHJ4*01 L123>T (112), V124>L (113)) [8.8.10] (1-117) -*Homo sapiens*IGHG2*01 CH1-bisagra-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada(*Homo sapiens*IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dímero (219-219":220-220":223-223":226-226")-tetrakisdisulfuro

p. 95 **vorapaxarum**
vorapaxar

replace the chemical name by the following

ethyl [(1*R*,3*aR*,4*aR*,6*R*,8*aR*,9*S*,9*aS*)-9-[(1*E*)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethen-1-yl]-1-methyl-3-oxododecahydronaphtho[2,3-*c*]furan-6-yl]carbamate

* *"INN for pharmaceutical substances: Names for radicals, groups & others"* document available at / document disponible à / documento disponible en :

<http://www.who.int/medicines/services/inn/publication/en/index.html>

Electronic structure available on Mednet: <http://mednet.who.int/>

Structure électronique disponible sur Mednet: <http://mednet.who.int/>

Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.